UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒						QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~January 1,~~July 2, 2022


☐						TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______

Commission File Number 001-14423

PLEXUS CORP.

(Exact name of registrant as specified in charter)


Wisconsin						39-1344447
(State or other jurisdiction of incorporation)						(I.R.S. Employer Identification No.)

One Plexus Way

Neenah, Wisconsin 54957

(Address of principal executive offices) (Zip Code)

Telephone Number (920) 969-6000

(Registrant’s telephone number, including Area Code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.01 par value	PLXS	The Nasdaq Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~February 1,~~August 2, 2022, there were ~~28,096,789~~27,712,174 shares of common stock outstanding.

Table of Contents

PLEXUS CORP.

TABLE OF CONTENTS

~~January 1,~~July 2, 2022



PART I. FINANCIAL INFORMATION			3
ITEM 1. FINANCIAL STATEMENTS			3
Condensed Consolidated Statements of Comprehensive Income			3
Condensed Consolidated Balance Sheets			4
Condensed Consolidated Statements of Shareholders' Equity			5
Condensed ~~Consolidate~~d S ~~tatements~~Consolidated Statements of Cash Flows			6
Notes to Condensed Consolidated Financial Statements			7
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS			1821
"Safe Harbor" Cautionary Statement Under the Private Securities Litigation Reform Act of 1995			1821
Overview			1821
Results of Operations			2123
Liquidity of Capital Resources			2428
Disclosure About Critical Accounting Policies			2932
New Accounting Pronouncements			2932
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK			2932
ITEM 4. CONTROLS AND PROCEDURES			3033
PART II. OTHER INFORMATION			3033
ITEM 1A. Risk Factors			3033
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds			3033
ITEM 6. Exhibits			3134
SIGNATURES			3235

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PLEXUS CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands, except per share data)

Unaudited


		Three Months Ended					Three Months Ended				Nine Months Ended
		January 1, 2022		January 2, 2021			July 2, 2022		July 3, 2021		July 2, 2022		July 3, 2021
Net sales	Net sales	$	817,456	$	830,355	Net sales	$	981,341	$	814,387	$	2,687,520	$	2,525,627
Cost of sales	Cost of sales	747,460		751,078		Cost of sales	887,723		740,337		2,447,396		2,281,298
Gross profit	Gross profit	69,996		79,277		Gross profit	93,618		74,050		240,124		244,329
Selling and administrative expenses	Selling and administrative expenses	37,502		32,411		Selling and administrative expenses	44,057		36,439		122,232		107,136
Restructuring and impairment charges	Restructuring and impairment charges	2,021		—		Restructuring and impairment charges	—		1,238		2,021		3,267
Operating income	Operating income	30,473		46,866		Operating income	49,561		36,373		115,871		133,926
Other income (expense):	Other income (expense):					Other income (expense):
Interest expense	Interest expense	(3,046)		(4,086)		Interest expense	(3,923)		(3,190)		(10,314)		(11,094)
Interest income	Interest income	271		374		Interest income	318		308		851		1,072
Miscellaneous, net	Miscellaneous, net	(923)		(1,518)		Miscellaneous, net	(2,678)		(579)		(5,047)		(2,922)
Income before income taxes	Income before income taxes	26,775		41,636		Income before income taxes	43,278		32,912		101,361		120,982
Income tax expense	Income tax expense	3,352		5,437		Income tax expense	5,784		5,303		13,575		15,411
Net income	Net income	$	23,423	$	36,199	Net income	$	37,494	$	27,609	$	87,786	$	105,571
Earnings per share:	Earnings per share:					Earnings per share:
Basic	Basic	$	0.84	$	1.25	Basic	$	1.35	$	0.97	$	3.14	$	3.68
Diluted	Diluted	$	0.82	$	1.23	Diluted	$	1.33	$	0.95	$	3.09	$	3.60
Weighted average shares outstanding:	Weighted average shares outstanding:					Weighted average shares outstanding:
Basic	Basic	28,018		28,861		Basic	27,738		28,529		27,913		28,708
Diluted	Diluted	28,709		29,539		Diluted	28,179		29,068		28,452		29,298
Comprehensive income:	Comprehensive income:					Comprehensive income:
Net income	Net income	$	23,423	$	36,199	Net income	$	37,494	$	27,609	$	87,786	$	105,571
Other comprehensive (loss) income:	Other comprehensive (loss) income:					Other comprehensive (loss) income:
Derivative instrument and other fair value adjustments	Derivative instrument and other fair value adjustments	1,272		4,055		Derivative instrument and other fair value adjustments	(3,239)		(1,218)		(1,531)		(1,719)
Foreign currency translation adjustments	Foreign currency translation adjustments	(1,578)		8,700		Foreign currency translation adjustments	(10,873)		1,434		(16,779)		6,730
Other comprehensive (loss) income	Other comprehensive (loss) income	(306)		12,755		Other comprehensive (loss) income	(14,112)		216		(18,310)		5,011
Total comprehensive income	Total comprehensive income	$	23,117	$	48,954	Total comprehensive income	$	23,382	$	27,825	$	69,476	$	110,582

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

PLEXUS CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except per share data)

Unaudited


		January 1, 2022		October 2, 2021			July 2, 2022		October 2, 2021
ASSETS	ASSETS					ASSETS
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	217,067	$	270,172	Cash and cash equivalents	$	276,608	$	270,172
Restricted cash	Restricted cash	1,324		341		Restricted cash	1,222		341
Accounts receivable, net of allowances of $1,753 and $1,188, respectively		589,253		519,684
Accounts receivable, net of allowances of $2,499 and $1,188, respectively						Accounts receivable, net of allowances of $2,499 and $1,188, respectively	613,510		519,684
Contract assets	Contract assets	105,450		115,283		Contract assets	128,050		115,283
Inventories, net	Inventories, net	1,185,915		972,312		Inventories, net	1,561,264		972,312
Prepaid expenses and other	Prepaid expenses and other	62,470		53,094		Prepaid expenses and other	73,771		53,094
Total current assets	Total current assets	2,161,479		1,930,886		Total current assets	2,654,425		1,930,886
Property, plant and equipment, net	Property, plant and equipment, net	414,981		395,094		Property, plant and equipment, net	429,990		395,094
Operating lease right-of-use assets	Operating lease right-of-use assets	69,519		72,087		Operating lease right-of-use assets	64,293		72,087
Deferred income taxes	Deferred income taxes	27,346		27,385		Deferred income taxes	26,919		27,385
Other assets	Other assets	36,321		36,441		Other assets	28,836		36,441
Total non-current assets	Total non-current assets	548,167		531,007		Total non-current assets	550,038		531,007
Total assets	Total assets	$	2,709,646	$	2,461,893	Total assets	$	3,204,463	$	2,461,893

LIABILITIES AND SHAREHOLDERS’ EQUITY	LIABILITIES AND SHAREHOLDERS’ EQUITY					LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:	Current liabilities:					Current liabilities:
Current portion of long-term debt and finance lease obligations	Current portion of long-term debt and finance lease obligations	$	151,417	$	66,313	Current portion of long-term debt and finance lease obligations	$	250,012	$	66,313
Accounts payable	Accounts payable	711,248		634,969		Accounts payable	853,203		634,969
Customer deposits	Customer deposits	265,759		204,985		Customer deposits	390,779		204,985
Accrued salaries and wages	Accrued salaries and wages	57,221		75,394		Accrued salaries and wages	68,386		75,394
Other accrued liabilities	Other accrued liabilities	180,840		147,042		Other accrued liabilities	298,363		147,042
Total current liabilities	Total current liabilities	1,366,485		1,128,703		Total current liabilities	1,860,743		1,128,703
Long-term debt and finance lease obligations, net of current portion	Long-term debt and finance lease obligations, net of current portion	187,075		187,033		Long-term debt and finance lease obligations, net of current portion	184,707		187,033
Long-term accrued income taxes payable	Long-term accrued income taxes payable	47,974		47,974		Long-term accrued income taxes payable	42,167		47,974
Long-term operating lease liabilities	Long-term operating lease liabilities	36,343		37,970		Long-term operating lease liabilities	32,270		37,970
Deferred income taxes payable	Deferred income taxes payable	5,307		5,677		Deferred income taxes payable	6,289		5,677
Other liabilities	Other liabilities	22,367		26,304		Other liabilities	20,097		26,304
Total non-current liabilities	Total non-current liabilities	299,066		304,958		Total non-current liabilities	285,530		304,958
Total liabilities	Total liabilities	1,665,551		1,433,661		Total liabilities	2,146,273		1,433,661
Commitments and contingencies	Commitments and contingencies	0		0		Commitments and contingencies	0		0
Shareholders’ equity:	Shareholders’ equity:					Shareholders’ equity:
Preferred stock, $0.01 par value, 5,000 shares authorized, none issued or outstanding	Preferred stock, $0.01 par value, 5,000 shares authorized, none issued or outstanding	—		—		Preferred stock, $0.01 par value, 5,000 shares authorized, none issued or outstanding	—		—
Common stock, $0.01 par value, 200,000 shares authorized, 53,909 and 53,849 shares issued, respectively, and 27,997 and 28,047 shares outstanding, respectively		539		538
Common stock, $0.01 par value, 200,000 shares authorized, 54,079 and 53,849 shares issued, respectively, and 27,712 and 28,047 shares outstanding, respectively						Common stock, $0.01 par value, 200,000 shares authorized, 54,079 and 53,849 shares issued, respectively, and 27,712 and 28,047 shares outstanding, respectively	541		538
Additional paid-in capital	Additional paid-in capital	642,654		639,778		Additional paid-in capital	647,169		639,778
Common stock held in treasury, at cost, 25,912 and 25,802 shares, respectively		(1,053,222)		(1,043,091)
Common stock held in treasury, at cost, 26,367 and 25,802 shares, respectively						Common stock held in treasury, at cost, 26,367 and 25,802 shares, respectively	(1,090,003)		(1,043,091)
Retained earnings	Retained earnings	1,457,414		1,433,991		Retained earnings	1,521,777		1,433,991
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(3,290)		(2,984)		Accumulated other comprehensive loss	(21,294)		(2,984)
Total shareholders’ equity	Total shareholders’ equity	1,044,095		1,028,232		Total shareholders’ equity	1,058,190		1,028,232
Total liabilities and shareholders’ equity	Total liabilities and shareholders’ equity	$	2,709,646	$	2,461,893	Total liabilities and shareholders’ equity	$	3,204,463	$	2,461,893

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

PLEXUS CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in thousands)

Unaudited


		Three Months Ended					Three Months Ended				Nine Months Ended
		January 1, 2022		January 2, 2021			July 2, 2022		July 3, 2021		July 2, 2022		July 3, 2021
Common stock - shares outstanding	Common stock - shares outstanding					Common stock - shares outstanding
Beginning of period	Beginning of period	28,047		29,002		Beginning of period	27,859		28,659		28,047		29,002
Exercise of stock options and vesting of other share-based awards	Exercise of stock options and vesting of other share-based awards	60		71		Exercise of stock options and vesting of other share-based awards	2		10		230		323
Treasury shares purchased	Treasury shares purchased	(110)		(307)		Treasury shares purchased	(149)		(292)		(565)		(948)
End of period	End of period	27,997		28,766		End of period	27,712		28,377		27,712		28,377

Total stockholders' equity, beginning of period	Total stockholders' equity, beginning of period	$	1,028,232	$	977,480	Total stockholders' equity, beginning of period	$	1,040,591	$	1,013,952	$	1,028,232	$	977,480
Common stock - par value	Common stock - par value					Common stock - par value
Beginning of period	Beginning of period	538		535		Beginning of period	541		538		538		535
Exercise of stock options and vesting of other share-based awards	Exercise of stock options and vesting of other share-based awards	1		1		Exercise of stock options and vesting of other share-based awards	—		—		3		3
End of period	End of period	539		536		End of period	541		538		541		538
Additional paid-in capital	Additional paid-in capital					Additional paid-in capital
Beginning of period	Beginning of period	639,778		621,564		Beginning of period	641,175		627,176		639,778		621,564
Share-based compensation expense	Share-based compensation expense	6,270		5,349		Share-based compensation expense	6,048		5,860		18,226		17,682
Exercise of stock options and vesting of other share-based awards, including tax withholding	Exercise of stock options and vesting of other share-based awards, including tax withholding	(3,394)		(2,054)		Exercise of stock options and vesting of other share-based awards, including tax withholding	(54)		115		(10,835)		(6,095)
End of period	End of period	642,654		624,859		End of period	647,169		633,151		647,169		633,151
Treasury stock	Treasury stock					Treasury stock
Beginning of period	Beginning of period	(1,043,091)		(934,639)		Beginning of period	(1,078,226)		(986,539)		(1,043,091)		(934,639)
Treasury shares purchased	Treasury shares purchased	(10,131)		(22,771)		Treasury shares purchased	(11,777)		(27,302)		(46,912)		(79,202)
End of period	End of period	(1,053,222)		(957,410)		End of period	(1,090,003)		(1,013,841)		(1,090,003)		(1,013,841)
Retained earnings	Retained earnings					Retained earnings
Beginning of period	Beginning of period	1,433,991		1,295,079		Beginning of period	1,484,283		1,373,041		1,433,991		1,295,079
Net income	Net income	23,423		36,199		Net income	37,494		27,609		87,786		105,571
End of period	End of period	1,457,414		1,331,278		End of period	1,521,777		1,400,650		1,521,777		1,400,650
Accumulated other comprehensive (loss) income
Accumulated other comprehensive loss						Accumulated other comprehensive loss
Beginning of period	Beginning of period	(2,984)		(5,059)		Beginning of period	(7,182)		(264)		(2,984)		(5,059)
Other comprehensive (loss) income	Other comprehensive (loss) income	(306)		12,755		Other comprehensive (loss) income	(14,112)		216		(18,310)		5,011
End of period	End of period	(3,290)		7,696		End of period	(21,294)		(48)		(21,294)		(48)
Total stockholders' equity, end of period	Total stockholders' equity, end of period	$	1,044,095	$	1,006,959	Total stockholders' equity, end of period	$	1,058,190	$	1,020,450	$	1,058,190	$	1,020,450

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

PLEXUS CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Unaudited


		Three Months Ended					Nine Months Ended
		January 1, 2022		January 2, 2021			July 2, 2022		July 3, 2021
Cash flows from operating activities	Cash flows from operating activities					Cash flows from operating activities
Net income	Net income	$	23,423	$	36,199	Net income	$	87,786	$	105,571
Adjustments to reconcile net income to net cash flows from operating activities:	Adjustments to reconcile net income to net cash flows from operating activities:					Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	Depreciation and amortization	15,489		14,836		Depreciation and amortization	46,842		45,785
Deferred income taxes	Deferred income taxes	35		366		Deferred income taxes	1,574		(1,032)
Share-based compensation expense and related charges	Share-based compensation expense and related charges	6,357		5,349		Share-based compensation expense and related charges	18,254		18,047
Provision for allowance for doubtful accounts	Provision for allowance for doubtful accounts	—		(2,346)		Provision for allowance for doubtful accounts	—		(2,405)
Other, net	Other, net	567		754		Other, net	1,419		1,538
Changes in operating assets and liabilities, excluding impacts of acquisition:	Changes in operating assets and liabilities, excluding impacts of acquisition:					Changes in operating assets and liabilities, excluding impacts of acquisition:
Accounts receivable	Accounts receivable	(70,159)		3,585		Accounts receivable	(100,850)		18,134
Contract assets	Contract assets	9,904		866		Contract assets	(12,672)		(66)
Inventories	Inventories	(214,416)		3,710		Inventories	(601,601)		(107,066)
Other current and non-current assets	Other current and non-current assets	(9,436)		(7,561)		Other current and non-current assets	(14,681)		(19,161)
Accrued income taxes payable	Accrued income taxes payable	1,121		3,277		Accrued income taxes payable	(6,707)		(14,533)
Accounts payable	Accounts payable	76,222		(23,514)		Accounts payable	228,509		62,315
Customer deposits	Customer deposits	60,743		(5,016)		Customer deposits	189,068		18,871
Other current and non-current liabilities	Other current and non-current liabilities	11,171		(23,789)		Other current and non-current liabilities	137,211		5,514
Cash flows (used in) provided by operating activities	Cash flows (used in) provided by operating activities	(88,979)		6,716		Cash flows (used in) provided by operating activities	(25,848)		131,512
Cash flows from investing activities	Cash flows from investing activities					Cash flows from investing activities
Payments for property, plant and equipment	Payments for property, plant and equipment	(33,246)		(15,880)		Payments for property, plant and equipment	(85,028)		(34,384)
Other, net	Other, net	(124)		113		Other, net	(105)		44
Cash flows used in investing activities	Cash flows used in investing activities	(33,370)		(15,767)		Cash flows used in investing activities	(85,133)		(34,340)
Cash flows from financing activities	Cash flows from financing activities					Cash flows from financing activities
Borrowings under debt agreements	Borrowings under debt agreements	181,134		4,177		Borrowings under debt agreements	524,000		242,687
Payments on debt and finance lease obligations	Payments on debt and finance lease obligations	(97,565)		(4,175)		Payments on debt and finance lease obligations	(343,207)		(336,536)
Debt issuance costs						Debt issuance costs	(898)		—
Repurchases of common stock	Repurchases of common stock	(10,131)		(22,771)		Repurchases of common stock	(46,912)		(79,202)
Proceeds from exercise of stock options	Proceeds from exercise of stock options	307		722		Proceeds from exercise of stock options	307		3,555
Payments related to tax withholding for share-based compensation	Payments related to tax withholding for share-based compensation	(3,702)		(2,775)		Payments related to tax withholding for share-based compensation	(11,142)		(9,647)
Cash flows provided by (used in) financing activities	Cash flows provided by (used in) financing activities	70,043		(24,822)		Cash flows provided by (used in) financing activities	122,148		(179,143)
Effect of exchange rate changes on cash and cash equivalents	Effect of exchange rate changes on cash and cash equivalents	184		2,912		Effect of exchange rate changes on cash and cash equivalents	(3,850)		1,574
Net decrease in cash and cash equivalents and restricted cash		(52,122)		(30,961)
Net increase (decrease) in cash and cash equivalents and restricted cash						Net increase (decrease) in cash and cash equivalents and restricted cash	7,317		(80,397)
Cash and cash equivalents and restricted cash:	Cash and cash equivalents and restricted cash:					Cash and cash equivalents and restricted cash:
Beginning of period	Beginning of period	270,513		387,894		Beginning of period	270,513		387,894
End of period	End of period	$	218,391	$	356,933	End of period	$	277,830	$	307,497

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

PLEXUS CORP. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED ~~JANUARY 1,~~JULY 2, 2022 AND ~~JANUARY 2,~~JULY 3, 2021

Unaudited

1. Basis of Presentation

Basis of Presentation:

The accompanying Condensed Consolidated Financial Statements included herein have been prepared by Plexus Corp. and its subsidiaries (together “Plexus” or the “Company”) without audit and pursuant to the rules and regulations of the United States (“U.S.”) Securities and Exchange Commission (“SEC”). The accompanying Condensed Consolidated Financial Statements reflect all adjustments, which include normal recurring adjustments necessary for the fair statement of the condensed consolidated financial position of the Company as of ~~January 1,~~July 2, 2022 and October 2, 2021, the results of operations and shareholders' equity for the three and nine months ended ~~January 1,~~July 2, 2022 and ~~January 2,~~July 3, 2021, and the cash flows for the same ~~three~~nine month periods.

The Company’s fiscal year ends on the Saturday closest to September 30. The Company uses a “4-4-5” weekly accounting system for the interim periods in each quarter. Each quarter, therefore, ends on a Saturday at the end of the 4-4-5 period. Periodically, an additional week must be added to the fiscal year to re-align with the Saturday closest to September 30. All fiscal quarters presented herein included 13 weeks.

Certain information and footnote disclosures, normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"), have been condensed or omitted pursuant to the SEC’s rules and regulations dealing with interim financial statements. However, the Company believes that the disclosures made in the Condensed Consolidated Financial Statements included herein are adequate to make the information presented not misleading. It is suggested that these Condensed Consolidated Financial Statements be read in conjunction with the Consolidated Financial Statements and notes thereto included in the Company’s 2021 Annual Report on Form 10-K.

The preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and notes thereto. The full extent to which ~~the~~ COVID-19 ~~outbreak~~and current global economic conditions will impact the Company's business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted. The Company has considered information available as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision of the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.

Recently Issued Accounting Pronouncements Not Yet Adopted:

The Company believes that no recently issued accounting standards will have a material impact on its Consolidated Financial Statements, or apply to its operations.

2. Inventories

Inventories as of ~~January 1,~~July 2, 2022 and October 2, 2021 consisted of the following (in thousands):


		January 1, 2022		October 2, 2021			July 2, 2022		October 2, 2021
Raw materials	Raw materials	$	1,051,889	$	860,538	Raw materials	$	1,404,740	$	860,538
Work-in-process	Work-in-process	57,381		48,356		Work-in-process	74,586		48,356
Finished goods	Finished goods	76,645		63,418		Finished goods	81,938		63,418
Total inventories, net	Total inventories, net	$	1,185,915	$	972,312	Total inventories, net	$	1,561,264	$	972,312

In certain circumstances, per contractual terms, customer deposits are received by the Company to offset inventory risks. The total amount of customer deposits related to inventory and included within current liabilities on the accompanying Condensed Consolidated Balance Sheets as of ~~January 1,~~July 2, 2022 and October 2, 2021 were ~~$260.3~~$379.8 million and $200.6 million, respectively.

Table of Contents

3. Debt, Finance Lease Obligations and Other Financing

Debt and finance lease obligations as of ~~January 1,~~July 2, 2022 and October 2, 2021, consisted of the following (in thousands):


		January 1, 2022		October 2, 2021			July 2, 2022		October 2, 2021
4.05% Senior Notes, due June 15, 2025	4.05% Senior Notes, due June 15, 2025	$	100,000	$	100,000	4.05% Senior Notes, due June 15, 2025	$	100,000	$	100,000
4.22% Senior Notes, due June 15, 2028	4.22% Senior Notes, due June 15, 2028	50,000		50,000		4.22% Senior Notes, due June 15, 2028	50,000		50,000
Borrowings under the revolving commitment		140,000		55,000
Borrowings under the Credit Facility						Borrowings under the Credit Facility	240,000		55,000
Finance lease and other financing obligations	Finance lease and other financing obligations	49,353		49,279		Finance lease and other financing obligations	46,328		49,279
Unamortized deferred financing fees	Unamortized deferred financing fees	(861)		(933)		Unamortized deferred financing fees	(1,609)		(933)
Total obligations	Total obligations	338,492		253,346		Total obligations	434,719		253,346
Less: current portion	Less: current portion	(151,417)		(66,313)		Less: current portion	(250,012)		(66,313)
Long-term debt and finance lease obligations, net of current portion	Long-term debt and finance lease obligations, net of current portion	$	187,075	$	187,033	Long-term debt and finance lease obligations, net of current portion	$	184,707	$	187,033

On June 15, 2018, the Company entered into a Note Purchase Agreement (the “2018 NPA”) pursuant to which it issued an aggregate of $150.0 million in principal amount of unsecured senior notes, consisting of $100.0 million in principal amount of 4.05% Series A Senior Notes, due on June 15, 2025, and $50.0 million in principal amount of 4.22% Series B Senior Notes, due on June 15, 2028 (collectively, the “2018 Notes”), in a private placement. The 2018 NPA includes customary operational and financial covenants with which the Company is required to comply, including, among others, maintenance of certain financial ratios such as a total leverage ratio and a minimum interest coverage ratio. The 2018 Notes may be prepaid in whole or in part at any time, subject to payment of a make-whole amount; interest on the 2018 Notes is payable semiannually. As of ~~January 1,~~July 2, 2022, the Company was in compliance with the covenants under the 2018 NPA.

On ~~May 15, 2019,~~June 9, 2022, the Company refinanced its then-existing senior unsecured revolving credit facility (as amended by that certain Amendment No. 1 to Credit Agreement dated April 29, 2020, the "Prior Credit Facility") by entering into a new 5-year ~~senior unsecured~~ revolving credit facility ~~(referred~~(collectively with the Prior Credit Facility, referred to as the "Credit Facility"), which expanded the maximum commitment from ~~$300.0~~$350.0 million to ~~$350.0~~$500.0 million and extended the maturity from ~~July 5, 2021 to~~ May 15, ~~2024.~~2024 to June 9, 2027. The maximum commitment under the Credit Facility may be further increased to ~~$600.0~~$750.0 million, generally by mutual agreement of the Company and the lenders, subject to certain customary conditions. During the ~~three~~nine months ended ~~January 1,~~July 2, 2022, the highest daily borrowing was ~~$186.0~~$327.0 million; the average daily borrowings were ~~$117.9~~$204.9 million. The Company borrowed ~~$181.0~~$524.0 million and repaid ~~$96.0~~$339.0 million of revolving borrowings ~~("revolving commitment")~~ under the Credit Facility during the ~~three~~nine months ended ~~January 1,~~July 2, 2022. As of ~~January 1,~~July 2, 2022, the Company was in compliance with all financial covenants relating to the Credit Facility, which are generally consistent with those in the 2018 NPA discussed above. The Company is required to pay a commitment fee on the daily unused ~~revolving commitment~~Credit Facility based on the Company's leverage ratio; the fee was 0.125% as of ~~January 1,~~July 2, 2022.

The fair value of the Company’s debt, excluding finance lease and other financing obligations, was $~~298.9~~383.5 million and ~~$217.1~~$217.1 million as of ~~January 1,~~July 2, 2022 and October 2, 2021, respectively. The carrying value of the Company's debt, excluding finance lease and other financing obligations, was ~~$290.0~~$390.0 million and $205.0 million as of ~~January 1,~~July 2, 2022 and October 2, 2021, respectively. If measured at fair value in the financial statements, the Company's debt would be classified as Level 2 in the fair value hierarchy. Refer to Note 4, "Derivatives and Fair Value Measurements," for further information regarding the Company's fair value calculations and classifications.

4. Derivatives and Fair Value Measurements

All derivatives are recognized in the accompanying Condensed Consolidated Balance Sheets at their estimated fair value. The Company uses derivatives to manage the variability of foreign currency obligations. The Company has cash flow hedges related to forecasted foreign currency obligations, in addition to non-designated hedges to manage foreign currency exposures associated with certain foreign currency denominated assets and liabilities. The Company does not enter into derivatives for speculative purposes.

~~Table of Contents~~

The Company designates some foreign currency exchange contracts as cash flow hedges of forecasted foreign currency expenses. Changes in the fair value of the derivatives that qualify as cash flow hedges are recorded in "Accumulated other comprehensive loss" in the accompanying Condensed Consolidated Balance Sheets until earnings are affected by the variability of the cash flows. In the next twelve months, the Company estimates that ~~$0.2~~$2.6 million of unrealized ~~gains,~~losses, net of tax, related to

Table of Contents

cash flow hedges will be reclassified from other comprehensive (loss) income into earnings. Changes in the fair value of the non-designated derivatives related to recognized foreign currency denominated assets and liabilities are recorded in "Miscellaneous, net" in the accompanying Condensed Consolidated Statements of Comprehensive Income.

The Company enters into forward currency exchange contracts for its operations in Malaysia and Mexico on a rolling basis. The Company had cash flow hedges outstanding with a notional value of ~~$117.9~~$141.4 million as of ~~January 1,~~July 2, 2022, and a notional value of $107.4 million as of October 2, 2021. These forward currency contracts fix the exchange rates for the settlement of future foreign currency obligations that have yet to be realized. The total fair value of the forward currency exchange contracts was a ~~$0.2~~$2.6 million ~~asset~~liability as of ~~January 1,~~July 2, 2022, and a $1.0 million liability as of October 2, 2021.

The Company had additional forward currency exchange contracts outstanding as of ~~January 1,~~July 2, 2022, with a notional value of ~~$32.3~~$52.4 million; there were $38.6 million such contracts outstanding as of October 2, 2021. The Company did not designate these derivative instruments as hedging instruments. The net settlement amount (fair value) related to these contracts is recorded on the Condensed Consolidated Balance Sheets as either a current or long-term asset or liability, depending on the term, and as an element of "Miscellaneous, net" in the Condensed Consolidated Statements of Comprehensive ~~income.~~Income. The total fair value of these derivatives was a ~~$0.1~~$0.4 million ~~asset~~liability as of ~~January 1,~~July 2, 2022, and a $0.2 million liability as of October 2, 2021.

The tables below present information regarding the fair values of derivative instruments (as defined in Note 1, "Description of Business and Significant Accounting Policies") and the effects of derivative instruments on the Company’s Condensed Consolidated Financial Statements:

Fair Values of Derivative Instruments (in thousands)

Derivative Assets

Derivative Liabilities

Derivative Assets

Derivative Liabilities

January 1,
2022

October 2,
2021

January 1,
2022

October 2,
2021

July 2,
2022

October 2,
2021

July 2,
2022

October 2,
2021

Derivatives designated as hedging instruments

Balance sheet
classification

Fair Value

Balance sheet
classification

Fair Value

Derivatives designated as hedging instruments

Balance sheet
classification

Fair Value

Balance sheet
classification

Fair Value

Foreign currency forward contracts

Prepaid expenses and other

356

Other accrued liabilities

127

1,119

Foreign currency forward contracts

Prepaid expenses and other

534

Other accrued liabilities

3,108

1,119

Fair Values of Derivative Instruments (in thousands)

Derivative Assets

Derivative Liabilities

Derivative Assets

Derivative Liabilities

January 1,
2022

October 2,
2021

January 1,
2022

October 2,
2021

July 2,
2022

October 2,
2021

July 2,
2022

October 2,
2021

Derivatives not designated as hedging instruments

Balance sheet
classification

Fair Value

Balance sheet
classification

Fair Value

Derivatives not designated as hedging instruments

Balance sheet
classification

Fair Value

Balance sheet
classification

Fair Value

Foreign currency forward contracts

Prepaid expenses and other

176

133

Other accrued liabilities

112

356

Foreign currency forward contracts

Prepaid expenses and other

153

133

Other accrued liabilities

566

356

The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Loss ("OCL") (in thousands)

for the Three Months Ended

Derivatives in cash flow hedging relationships

Amount of Gain Recognized in OCL on Derivatives

Derivatives in cash flow hedging relationships

Amount of (Loss) Gain Recognized in OCL on Derivatives

January 1, 2022

January 2, 2021

July 2, 2022

July 3, 2021

Foreign currency forward contracts

470

4,159

Foreign currency forward contracts

(3,588)

164

Derivative Impact on Gain (Loss) Recognized in Condensed Consolidated Statements of Comprehensive Income (in thousands)

Derivative Impact on (Loss) Gain Recognized in Condensed Consolidated Statements of Comprehensive Income (in thousands)

for the Three Months Ended

Derivatives in cash flow hedging relationships

Classification of (Loss) Gain Reclassified from Accumulated OCL into Income

Amount of (Loss) Gain Reclassified from Accumulated OCL into Income

Derivatives in cash flow hedging relationships

Classification of (Loss) Gain Reclassified from Accumulated OCL into Income

Amount of (Loss) Gain Reclassified from Accumulated OCL into Income

January 1, 2022

January 2, 2021

July 2, 2022

July 3, 2021

Foreign currency forward contracts

Cost of sales

(743)

Foreign currency forward contracts

Cost of sales

(322)

1,290

Foreign currency forward contracts

Selling and administrative expenses

(59)

Foreign currency forward contracts

Selling and administrative expenses

(27)

Derivatives not designated as hedging instruments

Location of (Loss) Gain Recognized on Derivatives in Income

Amount of (Loss) Gain on Derivatives Recognized in Income

July 2, 2022

July 3, 2021

Foreign currency forward contracts

Miscellaneous, net

(790)

Table of Contents

The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Loss ("OCL") (in thousands)

for the Nine Months Ended

Derivatives in cash flow hedging relationships

Amount of (Loss) Gain Recognized in OCL on Derivatives

July 2, 2022

July 3, 2021

Foreign currency forward contracts

(2,801)

1,575

Derivatives not designated as hedging instruments

Location of (Loss) Gain Recognized on Derivatives in Income

Amount of (Loss) Gain on Derivatives Recognized in Income

January 1, 2022

January 2, 2021

Derivative Impact on (Loss) Gain Recognized in Condensed Consolidated Statements of Comprehensive Income (in thousands)

for the Nine Months Ended

Derivatives in cash flow hedging relationships

Classification of (Loss) Gain Reclassified from Accumulated OCL into Income

Amount of (Loss) Gain Reclassified from Accumulated OCL into Income

July 2, 2022

July 3, 2021

Foreign currency forward contracts

Miscellaneous, net

(43)

530

Foreign currency forward contracts

Cost of sales

(1,174)

3,031

Foreign currency forward contracts

Selling and administrative expenses

(96)

263

Derivatives not designated as hedging instruments

Location of (Loss) Gain Recognized on Derivatives in Income

Amount of (Loss) Gain on Derivatives Recognized in Income

July 2, 2022

July 3, 2021

Foreign currency forward contracts

Miscellaneous, net

(1,615)

380

Fair Value Measurements:

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (or exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses quoted market prices when available or discounted cash flows to calculate fair value. The accounting guidance establishes a fair value hierarchy based on three levels of inputs that may be used to measure fair value. The input levels are:

Level 1: Quoted (observable) market prices in active markets for identical assets or liabilities.

Level 2: Inputs other than Level 1 that are observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the asset or liability.

The following table lists the fair values of assets of the Company’s derivatives as of ~~January 1,~~July 2, 2022 and October 2, 2021, by input level:


Fair Value Measurements Using Input Levels Asset/(Liability) (in thousands)	Fair Value Measurements Using Input Levels Asset/(Liability) (in thousands)									Fair Value Measurements Using Input Levels Asset/(Liability) (in thousands)
Fiscal year ended January 1, 2022		Level 1		Level 2		Level 3		Total
July 2, 2022										July 2, 2022	Level 1		Level 2		Level 3		Total
Derivatives	Derivatives									Derivatives
Foreign currency forward contracts	Foreign currency forward contracts	$	—	$	293	$	—	$	293	Foreign currency forward contracts	$	—	$	(2,987)	$	—	$	(2,987)

Fiscal year ended October 2, 2021
October 2, 2021										October 2, 2021
Derivatives	Derivatives									Derivatives
Foreign currency forward contracts	Foreign currency forward contracts	$	—	$	(1,266)	$	—	$	(1,266)	Foreign currency forward contracts	$	—	$	(1,266)	$	—	$	(1,266)

The fair value of foreign currency forward contracts is determined using a market approach, which includes obtaining directly or indirectly observable values from third parties active in the relevant markets. Inputs in the fair value of the foreign currency forward contracts include prevailing forward and spot prices for currency.

Table of Contents

5. Income Taxes

Income tax expense for the three and nine months ended ~~January 1,~~July 2, 2022 was ~~$3.4~~$5.8 million and $13.6 million, respectively, compared to ~~$5.4~~$5.3 million and $15.4 million for the three and nine months ended ~~January 2, 2021.~~July 3, 2021, respectively.

~~The effective tax rates for the three months ended January 1, 2022 and January 2, 2021 were 12.5% and 13.1%, respectively.~~ The effective tax rate for the three and nine months ended ~~January 1,~~July 2, 2022 ~~decreased from~~was 13.4% compared to the effective tax ~~rate~~rates of 16.1% and 12.7% for the three and nine months ended July 3, 2021, respectively. The decrease for the three months ended ~~January~~July 2, 2022 compared to the three months ended July 3, 2021, ~~primarily~~was due to ~~additional discrete tax benefits of $0.6 million partially offset by~~ a change in the geographic distribution of pre-tax book ~~income.~~income, partially offset by an increase in discrete tax expenses of $1.4 million. The increase for the nine months ended July 2, 2022 compared to the nine months ended July 3, 2021, was due to a change in the geographic distribution of pre-tax book income and an increase in discrete tax expenses of $2.0 million.

The amount of unrecognized tax benefits recorded for uncertain tax positions increased by ~~$0.5~~$1.5 million for the three months ended ~~January 1,~~July 2, 2022. The Company recognizes accrued interest and penalties on uncertain tax positions as a component of income tax expense. The amount of interest and penalties recorded for the three and nine months ended ~~January 1,~~July 2, 2022 was ~~not material.~~

~~Table of Contents~~

$0.2 million.

One or more uncertain tax positions may be settled within the next 12 months. Settlement of these matters is not expected to have a material effect on the Company's consolidated results of operations, financial position and cash flows. The Company is not currently under examination by taxing authorities in the ~~U.S. The Company is under audit in a~~U.S or any foreign ~~jurisdiction but a settlement is not expected to have a material impact.~~

jurisdiction.

The Company maintains valuation allowances when it is more likely than not that all or a portion of a net deferred tax asset will not be realized. During the three months ended ~~January 1,~~July 2, 2022, the Company released a full valuation allowance for a jurisdiction within the EMEA segment related to the settlement of an income tax audit. The company continued to record a full valuation allowance against its net deferred tax assets in certain jurisdictions within the EMEA segment and a partial valuation against its net deferred tax assets in certain jurisdictions within the AMER segment, as it was more likely than not that these assets would not be fully realized based primarily on historical performance. The Company will continue to provide a valuation allowance against its net deferred tax assets in each of the applicable jurisdictions going forward until it determines it is more likely than not that the deferred tax assets will be realized.

6. Earnings Per Share

The following is a reconciliation of the amounts utilized in the computation of basic and diluted earnings per share for the three and nine months ended ~~January 1,~~July 2, 2022 and ~~January 2,~~July 3, 2021 (in thousands, except per share amounts):


		Three Months Ended					Three Months Ended				Nine Months Ended
		January 1, 2022		January 2, 2021			July 2, 2022		July 3, 2021		July 2, 2022		July 3, 2021
Net income	Net income	$	23,423	$	36,199	Net income	$	37,494	$	27,609	$	87,786	$	105,571
Basic weighted average common shares outstanding	Basic weighted average common shares outstanding	28,018		28,861		Basic weighted average common shares outstanding	27,738		28,529		27,913		28,708
Dilutive effect of share-based awards and options outstanding	Dilutive effect of share-based awards and options outstanding	691		678		Dilutive effect of share-based awards and options outstanding	441		539		539		590
Diluted weighted average shares outstanding	Diluted weighted average shares outstanding	28,709		29,539		Diluted weighted average shares outstanding	28,179		29,068		28,452		29,298
Earnings per share:	Earnings per share:					Earnings per share:
Basic	Basic	$	0.84	$	1.25	Basic	$	1.35	$	0.97	$	3.14	$	3.68
Diluted	Diluted	$	0.82	$	1.23	Diluted	$	1.33	$	0.95	$	3.09	$	3.60

For the three and nine months ended ~~January 1,~~July 2, 2022 ~~and January 2, 2021,~~ there were ~~0 antidilutive awards.~~no anti-dilutive shares. For the three and nine months ended July 3, 2021, share-based awards for less than 0.1 million shares were not included in the computation of diluted earnings per share as they were antidilutive.

See also Note 12, "Shareholders' Equity," for information regarding the Company's share repurchase plans.

Table of Contents

7. Leases

The components of lease expense for the three and nine months ended ~~January 1,~~July 2, 2022 and ~~January 2,~~July 3, 2021 were as follows (in thousands):


		Three Months Ended					Three Months Ended				Nine Months Ended
		January 1, 2022		January 2, 2021			July 2, 2022		July 3, 2021		July 2, 2022		July 3, 2021
Finance lease expense:	Finance lease expense:					Finance lease expense:
Amortization of right-of-use assets	Amortization of right-of-use assets	$	1,693	$	1,016	Amortization of right-of-use assets	$	1,606	$	1,541	$	4,966	$	4,692
Interest on lease liabilities	Interest on lease liabilities	1,222		1,203		Interest on lease liabilities	1,262		1,229		3,713		3,669
Operating lease expense	Operating lease expense	2,857		2,752		Operating lease expense	2,912		2,697		8,607		8,146
Other lease expense	Other lease expense	1,404		1,253		Other lease expense	1,712		1,024		4,559		3,543
Total	Total	$	7,176	$	6,224	Total	$	7,492	$	6,491	$	21,845	$	20,050

Based on the nature of the right-of-use ("ROU") asset, amortization of finance lease ROU assets, operating lease expense and other lease expense are recorded within either cost of goods sold or selling and administrative expenses and interest on finance lease liabilities is recorded within interest expense on the Condensed Consolidated Statements of Comprehensive Income. Other lease expense includes lease expense for leases with an estimated total term of twelve months or less and variable lease expense related to variations in lease payments as a result of a change in factors or circumstances occurring after the lease possession date.

~~Table of Contents~~

The following tables sets forth the amount of lease assets and lease liabilities included in the Company’s Condensed Consolidated Balance Sheets (in thousands):


		Financial Statement Line Item	January 1, 2022		October 2, 2021			Financial Statement Line Item	July 2, 2022		October 2, 2021
ASSETS	ASSETS						ASSETS
Finance lease assets	Finance lease assets	Property, plant and equipment, net	$	38,842	$	38,657	Finance lease assets	Property, plant and equipment, net	$	36,099	$	38,657
Operating lease assets	Operating lease assets	Operating lease right-of-use assets	69,519		72,087		Operating lease assets	Operating lease right-of-use assets	64,293		72,087
Total lease assets	Total lease assets		$	108,361	$	110,744	Total lease assets		$	100,392	$	110,744

LIABILITIES AND SHAREHOLDERS' EQUITY	LIABILITIES AND SHAREHOLDERS' EQUITY						LIABILITIES AND SHAREHOLDERS' EQUITY
Current	Current						Current
Finance lease liabilities	Finance lease liabilities	Current portion of long-term debt and finance lease obligations	$	4,586	$	4,616	Finance lease liabilities	Current portion of long-term debt and finance lease obligations	$	3,705	$	4,616
Operating lease liabilities	Operating lease liabilities	Other accrued liabilities	9,507		9,877		Operating lease liabilities	Other accrued liabilities	8,640		9,877
Non-current	Non-current						Non-current
Finance lease liabilities	Finance lease liabilities	Long-term debt and finance lease obligations, net of current portion	37,379		36,919		Finance lease liabilities	Long-term debt and finance lease obligations, net of current portion	36,173		36,919
Operating lease liabilities	Operating lease liabilities	Long-term operating lease liabilities	36,343		37,970		Operating lease liabilities	Long-term operating lease liabilities	32,270		37,970
Total lease liabilities	Total lease liabilities		$	87,815	$	89,382	Total lease liabilities		$	80,788	$	89,382

As of July 2, 2022 we had $8.1 million of payments related to leases signed but not yet commenced. These leases will commence in the next twelve months, with lease terms between 3 and 25 years.

8. Share-Based Compensation

The Company recognized ~~$6.3~~$6.0 million and ~~$5.3~~$18.2 million of compensation expense associated with share-based awards for the three and nine months ended ~~January 1,~~July 2, 2022, respectively, and ~~January 2,~~$6.3 million and $18.1 million for the three and nine months ended July 3, 2021, respectively.

Table of Contents

Performance stock units ("PSUs") are payable in shares of the Company's common ~~stock.~~stock and have a performance period of three years. For PSUs, ~~issued in fiscal year 2020 and earlier, the PSUs~~50% vest based on the relative total shareholder return ("TSR") of the Company's common stock as compared to the companies in the Russell 3000 ~~index,~~Index for grants issued in fiscal 2020 and prior and the S&P 400 Index for grants issued in fiscal 2021 and beyond. Both are a market ~~condition, and~~condition. The remaining 50% of PSUs vest based upon a three-point annual average of the Company's absolute economic return, a performance condition, with grants made in fiscal 2021 and beyond being subject to an individual year minimum and maximum absolute economic return. The vesting and payout of awards will range between 0% and 200% of the shares granted based upon metrics during a performance period for PSUs based on economic return and PSUs based on TSR compared to the Russell 3000 Index. For PSUs based on TSR compared to the S&P 400 Index, the vesting and payout of awards will range between 0% and 150% of shares granted. Payout at target, 100% of the shares granted, will occur if the TSR of Plexus stock is at the 50th percentile of companies in the Russell 3000 Index or S&P 400 Index during the performance period and if a 2.5% average economic return is achieved over the performance period of three years, a performance condition. In the first quarter of fiscal 2021, the Company updated the market condition for PSUs based on TSR to the S&P 400 index for all future PSU grants, including those granted in fiscal year 2021. The Company uses the Monte Carlo valuation model to determine the fair value of PSUs at the date of grant for PSUs that vest based on the relative TSR of the Company's common stock. The Company uses its stock price on grant date as the fair value assigned to PSUs that vest based on the Company's economic return performance.years. The number of shares that may be issued pursuant to PSUs ranges from zero to 0.5 million and is dependent upon the Company's TSR and economic return performance over the applicable performance periods.

The Company recognizes share-based compensation expense over the share-based awards' vesting period.

9. Litigation

The Company is party to lawsuits in the ordinary course of business. Management does not believe that these proceedings, individually or in the aggregate, will have a material positive or adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

~~Table of Contents~~

10. Reportable Segments

Reportable segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or group, in assessing performance and allocating resources. The Company uses an internal management reporting system, which provides important financial data to evaluate performance and allocate the Company’s resources on a regional basis. Net sales for the segments are attributed to the region in which the product is manufactured or the service is performed. The services provided, manufacturing processes used, class of customers serviced and order fulfillment processes used are similar and generally interchangeable across the segments. A segment’s performance is evaluated based upon its operating income (loss). A segment’s operating income (loss) includes its net sales less cost of sales and selling and administrative expenses, but excludes corporate and other expenses. Corporate and other expenses primarily represent corporate selling and administrative expenses, and restructuring costs and other charges, if any. These costs are not allocated to the segments, as management excludes such costs when assessing the performance of the segments. Inter-segment transactions are generally recorded at amounts that approximate arm’s length transactions. The accounting policies for the segments are the same as for the Company taken as a whole.

Table of Contents

Information about the Company’s 3 reportable segments for the three and nine months ended ~~January 1,~~July 2, 2022 and ~~January 2,~~July 3, 2021 is as follows (in thousands):


		Three Months Ended					Three Months Ended				Nine Months Ended
		January 1, 2022		January 2, 2021			July 2, 2022		July 3, 2021		July 2, 2022		July 3, 2021
Net sales:	Net sales:					Net sales:
AMER	AMER	$	277,346	$	327,567	AMER	$	342,572	$	318,898	$	931,123	$	1,011,162
APAC	APAC	491,672		451,302		APAC	586,305		446,915		1,611,862		1,357,089
EMEA	EMEA	72,863		78,723		EMEA	84,177		76,519		230,742		238,564
Elimination of inter-segment sales	Elimination of inter-segment sales	(24,425)		(27,237)		Elimination of inter-segment sales	(31,713)		(27,945)		(86,207)		(81,188)
		$	817,456	$	830,355		$	981,341	$	814,387	$	2,687,520	$	2,525,627

Operating income (loss):	Operating income (loss):					Operating income (loss):
AMER	AMER	$	1,790	$	16,482	AMER	$	16,976	$	9,191	$	26,535	$	51,876
APAC	APAC	60,688		61,542		APAC	67,286		57,068		188,834		176,722
EMEA	EMEA	956		(988)		EMEA	2,597		58		4,043		(2,548)
Corporate and other costs	Corporate and other costs	(32,961)		(30,170)		Corporate and other costs	(37,298)		(29,944)		(103,541)		(92,124)
		$	30,473	$	46,866		$	49,561	$	36,373	$	115,871	$	133,926
Other income (expense):	Other income (expense):					Other income (expense):
Interest expense	Interest expense	$	(3,046)	$	(4,086)	Interest expense	$	(3,923)	$	(3,190)	$	(10,314)	$	(11,094)
Interest income	Interest income	271		374		Interest income	318		308		851		1,072
Miscellaneous, net	Miscellaneous, net	(923)		(1,518)		Miscellaneous, net	(2,678)		(579)		(5,047)		(2,922)
Income before income taxes	Income before income taxes	$	26,775	$	41,636	Income before income taxes	$	43,278	$	32,912	$	101,361	$	120,982


		January 1, 2022		October 2, 2021			July 2, 2022		October 2, 2021
Total assets:	Total assets:					Total assets:
AMER	AMER	$	869,801	$	789,385	AMER	$	1,054,665	$	789,385
APAC	APAC	1,457,341		1,283,124		APAC	1,763,076		1,283,124
EMEA	EMEA	276,273		275,122		EMEA	296,689		275,122
Corporate and eliminations	Corporate and eliminations	106,231		114,262		Corporate and eliminations	90,033		114,262
		$	2,709,646	$	2,461,893		$	3,204,463	$	2,461,893

~~Table of Contents~~

11. Guarantees

The Company offers certain indemnifications under its customer manufacturing agreements. In the normal course of business, the Company may from time to time be obligated to indemnify its customers or its customers’ customers against damages or liabilities arising out of the Company’s negligence, misconduct, breach of contract, or infringement of third-party intellectual property rights. Certain agreements have extended broader indemnification, and while most agreements have contractual limits, some do not. However, the Company generally does not provide for such indemnities and seeks indemnification from its customers for damages or liabilities arising out of the Company’s adherence to customers’ specifications or designs or use of materials furnished, or directed to be used, by its customers. The Company does not believe its obligations under such indemnities are material.

In the normal course of business, the Company also provides its customers a limited warranty covering workmanship, and in some cases materials, on products manufactured by the Company. Such warranty generally provides that products will be free from defects in the Company’s workmanship and meet mutually agreed-upon specifications for periods generally ranging from 12 months to 24 months. The Company’s obligation is generally limited to correcting, at its expense, any defect by repairing or replacing such defective product. The Company’s warranty generally excludes defects resulting from faulty customer-supplied components, design defects or damage caused by any party or cause other than the Company.

Table of Contents

The Company provides for an estimate of costs that may be incurred under its limited warranty at the time product revenue is recognized and establishes additional reserves for specifically identified product issues. These costs primarily include labor and materials, as necessary, associated with repair or replacement and are included in the Company's accompanying Condensed Consolidated Balance Sheets in "other accrued liabilities." The primary factors that affect the Company’s warranty liability include the value and the number of shipped units and historical and anticipated rates of warranty claims. As these factors are impacted by actual experience and future expectations, the Company assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.

Below is a table summarizing the activity related to the Company’s limited warranty liability for the ~~three~~nine months ended ~~January 1,~~July 2, 2022 and ~~January 2,~~July 3, 2021 (in thousands):


		Three Months Ended					Nine Months Ended
		January 1, 2022		January 2, 2021			July 2, 2022		July 3, 2021
Reserve balance, beginning of period	Reserve balance, beginning of period	$	6,645	$	6,386	Reserve balance, beginning of period	$	6,645	$	6,386
Accruals for warranties issued during the period	Accruals for warranties issued during the period	1,258		465		Accruals for warranties issued during the period	2,431		2,102
Settlements (in cash or in kind) during the period	Settlements (in cash or in kind) during the period	(741)		(1,066)		Settlements (in cash or in kind) during the period	(2,032)		(2,434)
Reserve balance, end of period	Reserve balance, end of period	$	7,162	$	5,785	Reserve balance, end of period	$	7,044	$	6,054

12. Shareholders' Equity

On August 20, 2019, the Board of Directors approved a share repurchase program under which the Company is authorized to repurchase $50.0 million of its common stock (the "2019 Program"). During the ~~three~~nine months ended ~~January 2,~~July 3, 2021, the Company completed the 2019 Program by repurchasing 73,560 shares under this program for $5.3 million at an average price of $72.44 per share.

On August 13, 2020, the Board of Directors approved a share repurchase program under which the Company is authorized to repurchase up to $50.0 million of its common stock (the "2021 Program"). On November 18, 2020, the Board of Directors approved an additional $50.0 million in share repurchase authority under the ~~existing~~ 2021 Program such that there then existed a total of $100.0 million in share repurchase authority under the program. The 2021 Program commenced upon completion of the 2019 Program. During the three months ended ~~January 2,~~July 3, 2021, the Company repurchased ~~233,511~~291,898 shares under this program for ~~$17.5~~$27.3 million at an average price of ~~$74.70~~$93.53 per share. During the nine months ended July 3, 2021, the Company repurchased 874,706 shares under this program for $73.9 million at an average price of $84.45 per share.

On August 11, 2021, the Board of Directors approved a ~~new~~ share repurchase program that authorizes the Company to repurchase up to $50.0 million of its common stock (the "2022 Program"). The 2022 Program commenced upon completion of the 2021 Program. ~~The 2022 Program has no expiration.~~ During the three months ended ~~January 1,~~July 2, 2022, the Company repurchased ~~110,440~~148,571 shares under this program for ~~$10.2~~$11.7 million at an average price of ~~$91.74~~$79.27 per share. During the nine months ended July 2, 2022, the Company repurchased 564,718 shares under this program for $46.9 million at an average price of $83.07 per share. As of ~~January 1,~~July 2, 2022, ~~$36.7 million of authority remained under~~the Company completed the 2022 ~~Program.~~Program, and there is no remaining authority for share repurchases.

All shares repurchased under the aforementioned programs were recorded as treasury stock.

~~Table of Contents~~

13. Trade Accounts Receivable Sale Programs

The Company has Master Accounts Receivable Purchase Agreements with MUFG Bank, New York Branch (formerly known as The Bank of Tokyo-Mitsubishi UFJ, Ltd.) (the "MUFG RPA"), HSBC Bank (China) Company Limited, Xiamen branch (the "HSBC RPA") and other unaffiliated financial institutions, under which the Company may elect to sell receivables; at a discount. All facilities are uncommitted facilities. The maximum facility amount under the MUFG RPA as of ~~January 1,~~July 2, 2022 is $340.0 million. The maximum facility amount under the HSBC RPA as of ~~January 1,~~July 2, 2022 is $60.0 million. The MUFG RPA will be automatically extended each year unless any party gives no less than 10 days prior notice that the agreement should not be extended. The terms of the HSBC RPA are generally consistent with the terms of the MUFG RPA previously discussed.

Transfers of receivables under the programs are accounted for as sales and, accordingly, receivables sold under the programs are excluded from accounts receivable on the Condensed Consolidated Balance Sheets and are reflected as cash provided by

Table of Contents

operating activities on the Condensed Consolidated Statements of Cash Flows. Proceeds from the transfer reflect the face value of the receivables less a discount. The sale discount is recorded within "Miscellaneous, net" in the Condensed Consolidated Statements of Comprehensive Income in the period of the sale. The Company continues servicing receivables sold and performing all accounts receivable administrative functions, and in exchange receives a servicing fee, under both the MUFG RPA and HSBC RPA. Servicing fees related to trade accounts receivable programs recognized during the three and ninemonths ended ~~January 1,~~July 2, 2022 and ~~January 2,~~July 3, 2021 were not material.

The Company sold ~~$148.0~~$213.6 million and ~~$198.4~~$180.6 million of trade accounts receivable under these programs, or their predecessors, during the three months ended ~~January 1,~~July 2, 2022 and ~~January 2,~~July 3, 2021, respectively, in exchange for cash proceeds of ~~$147.5~~$212.3 million and $~~197.8~~180.1 million, respectively.

The Company sold $563.8 million and $574.6 million of trade accounts receivable under these programs, or their predecessors, during the nine months ended July 2, 2022 and July 3, 2021, respectively, in exchange for cash proceeds of $561.3 million and$573.0 million, respectively.

As of ~~January 1,~~July 2, 2022 and October 2, 2021, ~~$151.0~~$216.9 million and $176.0 million, respectively, of accounts receivables sold under trade accounts receivable programs and subject to servicing by the Company remained outstanding and had not yet been collected.

14. Revenue from Contracts with Customers

Significant Judgments

Revenue is recognized over time for arrangements with customers for which: (i) the Company's performance does not create an asset with an alternative use to the Company, and (ii) the Company has an enforceable right to payment, including reasonable profit margin, for performance completed to date. Revenue recognized over time is estimated based on costs incurred to date plus a reasonable profit margin. If either of the two conditions noted above are not met to recognize revenue over time, revenue is recognized following the transfer of control of such products to the customer, which typically occurs upon shipment or delivery depending on the terms of the underlying arrangement.

The Company recognizes revenue when a contract exists and when, or as, it satisfies a performance obligation by transferring control of a product or service to a customer. Contracts are accounted for when they have approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer.

The Company generally enters into a master services arrangement that establishes the framework under which business will be conducted. These arrangements represent the master terms and conditions of the Company's services that apply to individual orders, but they do not commit the customer to work with, or to continue to work with, the Company nor do they obligate the customer to any specific volume or pricing of purchases. Moreover, these terms can be amended in appropriate situations.

Customer purchase orders are received for specific quantities with predominantly fixed pricing and delivery requirements. Thus, for the majority of our contracts, there is no guarantee of any revenue to the Company until a customer submits a purchase order. As a result, the Company generally considers its arrangement with a customer to be the combination of the master services arrangement and the purchase order. Most of the Company's arrangements with customers create a single performance obligation as the promise to transfer the individual manufactured product or service is capable of being distinct.

~~Table of Contents~~

The Company’s performance obligations are satisfied over time as work progresses or at a point in time. A performance obligation is satisfied over time if the Company has an enforceable right to payment, including a reasonable profit margin. Determining if an enforceable right to payment includes a reasonable profit margin requires judgment and is assessed on a contract by contract basis.

Generally, there are no subjective customer acceptance requirements or further obligations related to goods or services provided; if such requirements or obligations exist, then a sale is recognized at the time when such requirements are completed and such obligations are fulfilled.

The Company does not allow for a general right of return. Net sales include amounts billed to customers for shipping and handling and out-of-pocket expenses. The corresponding shipping and handling costs and out-of-pocket expenses are included

Table of Contents

in cost of sales. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from net sales.

Contract Costs

For contracts requiring over time revenue recognition, the selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. The Company uses a cost-based input measurement of progress because it best depicts the transfer of assets to the customer, which occurs as costs are incurred during the manufacturing process or as services are rendered. Under the cost-based measure of progress, the extent of progress towards completion is measured based on the costs incurred to date.

There were no other costs to obtain or fulfill customer contracts.

Disaggregated Revenue

The table below includes the Company’s revenue for the three and nine months ended ~~January 1,~~July 2, 2022 and ~~January 2,~~July 3, 2021 and disaggregated by geographic reportable segment and market sector (in thousands):


		Three Months Ended									Three Months Ended
		January 1, 2022									July 2, 2022
		Reportable Segment:									Reportable Segment:
		AMER		APAC		EMEA		Total			AMER		APAC		EMEA		Total
Market Sector:	Market Sector:									Market Sector:
Industrial	Industrial	$	83,245	$	265,275	$	15,307	$	363,827	Industrial	$	108,064	$	328,314	$	17,999	$	454,377
Healthcare/Life Sciences	Healthcare/Life Sciences	135,962		169,237		39,266		344,465		Healthcare/Life Sciences	171,697		184,202		44,900		400,799
Aerospace/Defense	Aerospace/Defense	55,750		35,743		17,671		109,164		Aerospace/Defense	59,972		45,980		20,213		126,165
External revenue	External revenue	274,957		470,255		72,244		817,456		External revenue	339,733		558,496		83,112		981,341
Inter-segment sales	Inter-segment sales	2,389		21,417		619		24,425		Inter-segment sales	2,839		27,809		1,065		31,713
Segment revenue	Segment revenue	$	277,346	$	491,672	$	72,863	$	841,881	Segment revenue	$	342,572	$	586,305	$	84,177	$	1,013,054


		Three Months Ended									Three Months Ended
		January 2, 2021									July 3, 2021
		Reportable Segment:									Reportable Segment:
		AMER		APAC		EMEA		Total			AMER		APAC		EMEA		Total
Market Sector:	Market Sector:									Market Sector:
Industrial	Industrial	$	122,026	$	238,248	$	17,768	$	378,042	Industrial	$	109,672	$	243,121	$	19,126	$	371,919
Healthcare/Life Sciences	Healthcare/Life Sciences	126,439		154,046		38,828		319,313		Healthcare/Life Sciences	143,033		144,874		36,529		324,436
Aerospace/Defense	Aerospace/Defense	76,980		34,259		21,761		133,000		Aerospace/Defense	64,038		33,614		20,380		118,032
External revenue	External revenue	325,445		426,553		78,357		830,355		External revenue	316,743		421,609		76,035		814,387
Inter-segment sales	Inter-segment sales	2,122		24,749		366		27,237		Inter-segment sales	2,155		25,306		484		27,945
Segment revenue	Segment revenue	$	327,567	$	451,302	$	78,723	$	857,592	Segment revenue	$	318,898	$	446,915	$	76,519	$	842,332

1617

Table of Contents


	Nine Months Ended
	July 2, 2022
	Reportable Segment:
	AMER		APAC		EMEA		Total
Market Sector:
Industrial	$	289,576	$	895,915	$	47,367	$	1,232,858
Healthcare/Life Sciences	451,514		518,538		128,460		1,098,512
Aerospace/Defense	182,935		120,646		52,569		356,150
External revenue	924,025		1,535,099		228,396		2,687,520
Inter-segment sales	7,098		76,763		2,346		86,207
Segment revenue	$	931,123	$	1,611,862	$	230,742	$	2,773,727


	Nine Months Ended
	July 3, 2021
	Reportable Segment:
	AMER		APAC		EMEA		Total
Market Sector:
Industrial	$	363,039	$	736,906	$	56,934	$	1,156,879
Healthcare/Life Sciences	424,499		448,783		120,234		993,516
Aerospace/Defense	216,206		99,193		59,833		375,232
External revenue	1,003,744		1,284,882		237,001		2,525,627
Inter-segment sales	7,418		72,207		1,563		81,188
Segment revenue	$	1,011,162	$	1,357,089	$	238,564	$	2,606,815

For ~~each~~the three and nine months ended July 2, 2022, approximately 83% and 85% of the Company's revenue, respectively, was recognized as the performance obligations for products and services were transferred over time. For the three and nine months ended ~~January 1, 2022 and January 2,~~July 3, 2021, approximately ~~87% and~~ 91% of the Company's revenue, respectively, was recognized as the performance obligations for products and services were transferred over time.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, contract assets and deferred revenue on the Company’s accompanying Condensed Consolidated Balance Sheets.

Contract Assets: For performance obligations satisfied at a point in time, billing occurs subsequent to revenue recognition, at which point the customer has been billed and the resulting asset is recorded within accounts receivable. For performance obligations satisfied over time as work progresses, the Company has an unconditional right to payment, which results in the recognition of contract assets. The following table summarizes the activity in the Company's contract assets during the ~~three~~nine months ended ~~January 1,~~July 2, 2022 and ~~January 2,~~July 3, 2021 (in thousands):


		Three Months Ended					Nine Months Ended
		January 1, 2022		January 2, 2021			July 2, 2022		July 3, 2021
Contract assets, beginning of period	Contract assets, beginning of period	$	115,283	$	113,946	Contract assets, beginning of period	$	115,283	$	113,946
Revenue recognized during the period	Revenue recognized during the period	709,723		753,565		Revenue recognized during the period	2,279,559		2,303,287
Amounts collected or invoiced during the period	Amounts collected or invoiced during the period	(719,556)		(754,286)		Amounts collected or invoiced during the period	(2,266,792)		(2,303,211)
Contract assets, end of period	Contract assets, end of period	$	105,450	$	113,225	Contract assets, end of period	$	128,050	$	114,022

Deferred Revenue: Deferred revenue is recorded when consideration is received from a customer prior to transferring goods or services to the customer under the terms of the contract, which is included in other accrued liabilities on the Condensed Consolidated Balance Sheets. As of ~~January 1,~~July 2, 2022 and October 2, 2021, the balance of advance payments from customers that

Table of Contents

remained in other accrued liabilities was ~~$133.2~~$251.1 million and $101.1 million, respectively. The advance payment is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect the company from the other party failing to adequately complete some or all of its obligations under the contract. Deferred revenue is recognized into revenue when all revenue recognition criteria are met. For performance obligations satisfied over time, recognition will occur as work progresses; otherwise deferred revenue will be recognized based upon shipping terms.

15. Restructuring and Impairment Charges

~~During the first quarter of fiscal 2022, the Company recorded $2.0 million of restructuring~~Restructuring and impairment ~~charges primarily due to employee severance costs associated with a facility transition in our APAC region. These~~ charges are recorded within restructuring and impairment charges on the Condensed Consolidated Statements of Comprehensive Income. Restructuring liabilities are recorded within other accrued liabilities on the Condensed Consolidated Balance Sheets.

For the three months ended July 2, 2022, the Company did not incur any restructuring and impairment charges. For the nine months ended July 2, 2022, the Company recorded $2.0 million of restructuring and charges primarily due to employee severance costs associated with a facility transition in the Company's APAC segment.

For the three months ended July 3, 2021, the Company incurred restructuring and impairment charges of $1.2 million, which consisted of severance from the reduction of the Company's workforce primarily in the AMER segment. For the nine months ended July 3, 2021, the Company incurred restructuring and impairment charges of $3.3 million, which consisted of severance from the reduction of the Company's workforce primarily in the AMER and EMEA segments.

The Company recognized a tax benefit of $0.2 million related to restructuring and impairment charges for the nine months ended July 2, 2022 and $0.1 million and $0.3 million related to restructuring charges in the three and nine months ended ~~January 1, 2022.~~July 3, 2021, respectively.

The Company's restructuring accrual activity for the three and nine months ended ~~January 1,~~July 2, 2022 and nine months ended July 3, 2021 is included in the table below (in thousands):


		Fixed Asset and Operating ROU Asset Impairment		Employee Termination and Severance Costs		Total			Fixed Asset and Operating ROU Asset Impairment		Employee Termination and Severance Costs		Total
Accrual balance, as of October 2, 2021	Accrual balance, as of October 2, 2021	$	—	$	71	$	71	Accrual balance, as of October 2, 2021	$	—	$	71	$	71
Restructuring and impairment costs	Restructuring and impairment costs	255		1,766		2,021		Restructuring and impairment costs	255		1,766		2,021
Amounts utilized	Amounts utilized	(255)		(75)		(330)		Amounts utilized	(255)		(75)		(330)
Accrual balance, as of January 1, 2022	Accrual balance, as of January 1, 2022	$	—	$	1,762	$	1,762	Accrual balance, as of January 1, 2022	$	—	$	1,762	$	1,762
Restructuring and impairment costs								Restructuring and impairment costs	—		—		—
Amounts utilized								Amounts utilized	—		(100)		(100)
Accrual balance, as of April 2, 2022								Accrual balance, as of April 2, 2022	$	—	$	1,662	$	1,662
Restructuring and impairment costs								Restructuring and impairment costs	—		—		—
Amounts utilized								Amounts utilized	—		(181)		(181)
Accrual balance, as of July 2, 2022								Accrual balance, as of July 2, 2022	$	—	$	1,481	$	1,481

Table of Contents


	Fixed Asset and Operating ROU Asset Impairment		Employee Termination and Severance Costs		Total
Accrual balance, as of January 2, 2021	$	—	$	22	$	22
Restructuring and impairment costs	—		2,029		2,029
Amounts utilized	—		(440)		(440)
Accrual balance, as of April 3, 2021	$	—	$	1,611	$	1,611
Restructuring and impairment costs	—		1,238		1,238
Amounts utilized	—		(1,997)		(1,997)
Accrual balance, as of July 3, 2021	$	—	$	852	$	852

There was 0no material restructuring activity for the three months ended January 2, 2021.

1720

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

"SAFE HARBOR" CAUTIONARY STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995:

The statements contained in this Form 10-Q that are guidance or which are not historical facts (such as statements in the future tense and statements including believe, expect, intend, plan, anticipate, goal, target and similar terms and concepts), including all discussions of periods which are not yet completed, are forward-looking statements that involve risks and uncertainties. These risks and uncertainties include the evolving effect, which may intensify, of COVID-19 on our employees, customers, suppliers, and logistics providers, including the impact of governmental actions being taken to curtail the spread of the virus. Other risks and uncertainties include, but are not limited to: the effect of inflationary pressures on our costs of production, profitability, and on the economic outlook of our markets; the effects of shortages and delays in obtaining components as a result of economic cycles, natural disasters or otherwise; the risk of customer delays, changes, cancellations or forecast inaccuracies in both ongoing and new programs; the lack of visibility of future orders, particularly in view of changing economic conditions; the economic performance of the industries, sectors and customers we serve; the effects of tariffs, trade disputes, trade agreements and other trade protection measures; the effects of the volume of revenue from certain sectors or programs on our margins in particular periods; our ability to secure new customers, maintain our current customer base and deliver product on a timely basis; the risks of concentration of work for certain customers; the particular risks relative to new or recent customers, programs or services, which risks include customer and other delays, start-up costs, potential inability to execute, the establishment of appropriate terms of agreements, and the lack of a track record of order volume and timing; the effects of start-up costs of new programs and facilities or the costs associated with the closure or consolidation of facilities; possible unexpected costs and operating disruption in transitioning programs, including transitions between Company facilities; the risk that new program wins and/or customer demand may not result in the expected revenue or profitability; the fact that customer orders may not lead to long-term relationships; our ability to manage successfully and execute a complex business model characterized by high product mix and demanding quality, regulatory, and other requirements; the risks associated with excess and obsolete inventory, including the risk that inventory purchased on behalf of our customers may not be consumed or otherwise paid for by the customer, resulting in an inventory write-off; risks related to information technology systems and data security; the ability to realize anticipated savings from restructuring or similar actions, as well as the adequacy of related charges as compared to actual expenses; increasing regulatory and compliance requirements; the effects of U.S. Tax Reform, any tax law changes as a result of change in U.S. presidential administration, and of related foreign jurisdiction tax developments; current or potential future barriers to the repatriation of funds that are currently held outside of the United States as a result of actions taken by other countries or otherwise; the potential effects of jurisdictional results on our taxes, tax rates, and our ability to use deferred tax assets and net operating losses; the weakness of areas of the global economy; the effect of changes in the pricing and margins of products; raw materials and component cost fluctuations; the potential effect of fluctuations in the value of the currencies in which we transact business; the effects of changes in economic conditions, political conditions and tax matters in the United States and in the other countries in which we do business (including as a result of the United Kingdom’s exit from the European Union); the potential effect of other world or local events or other events outside our control (such as the recent conflict between Russia and Ukraine, changes in energy prices, terrorism, global health epidemics and weather events); the impact of increased competition; an inability to successfully manage human capital; changes in financial accounting standards; and other risks detailed herein and in our other Securities and Exchange Commission filings, particularly in Risk Factors in our fiscal 2021 Form 10-K.

* * *

OVERVIEW

Plexus Corp. and its subsidiaries (together "Plexus," the "Company," or "we") participate in the Electronic Manufacturing Services ("EMS") industry. Since 1979, we have been partnering with companies to create the products that ~~Build~~build a ~~Better World~~better world by providing Design and Development, Supply Chain Solutions, New Product Introduction, Manufacturing and Aftermarket Services. We are a global leader that specializes in serving customers in industries with highly complex products and demanding regulatory environments. Plexus delivers customer service excellence to leading companies by providing innovative, comprehensive solutions throughout a product’s lifecycle. We engineer innovative solutions for customers in growth markets and focus on partnering with leading global companies in the Industrial, Healthcare/Life Sciences and Aerospace/Defense market sectors. We deliver comprehensive end-to-end solutions in the Americas ("AMER"), Asia-Pacific ("APAC") and Europe, Middle East and Africa ("EMEA") regions.

Table of Contents

The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to provide an analysis of both short-term results and future prospects from management’s perspective, including an assessment of the financial condition and results of operations, events and uncertainties that are not indicative of future operations and any other financial or statistical data that we believe will enhance the understanding of our company’s financial condition, cash flows and other changes in financial condition and results of operations.

The following information should be read in conjunction with our condensed consolidated financial statements included herein and "Risk Factors" included in Part II, Item 1A included herein as well as Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended October 2, 2021, and our "Safe Harbor" Cautionary Statement included ~~above .~~above.

~~COVID-19~~Current Events Update

We continue to monitor the global outbreak and spread of COVID-19 and take steps to mitigate the potential risks to us posed by its spread and related circumstances and impacts.

The health and safety of our employees is a top priority for us. We have progressively implemented measures to safeguard our employees from the COVID-19 infection and exposure and have made significant efforts to mitigate the effects of regulatory authority restrictions on our operations through a combination of adjustments in our shift patterns, flexible work arrangements, productivity improvements, facility enhancements to support social distancing and optimizing employee capability to work from home, if needed. These efforts will continue as requirements change, new risks are identified and infections impact us.

~~We have experienced labor shortages due to COVID-19 quarantines or workforce curtailments, particularly in Malaysia during fiscal 2021, as the virus spread.~~ The spread and resurgence of ~~the~~ COVID-19 ~~virus~~ from new variants in jurisdictions where we operate may make our ability to mitigate the impacts of the pandemic on our productivity more challenging.

We remain in close contact with our suppliers to understand the impacts of COVID-19 on their businesses and operations. Our suppliers may face challenges in maintaining an adequate workforce or securing materials from their own suppliers as a result of COVID-19. We have experienced, and expect to continue to experience, ~~during the remainder of fiscal 2022,~~ an inability to procure certain components and materials on a timely basis due to ~~worsening~~global supply chain ~~shortages~~constraints likely as a result of the COVID-19 ~~pandemic.~~pandemic and worsened by geopolitical conditions including the conflict in Ukraine. These constraints have impacted our ability to meet customer demand and will continue to inhibit our ability to capture the demand from our customers. We remain in close contact with our suppliers to understand the impacts on their businesses and operations and continue to take steps to validate ~~our suppliers’~~their ability to deliver to us on time. However, the extended lead times have required us to make additional investments in inventory to satisfy customer demand, which we expect to persist.

Worsening supply chain constraints have impacted our ability to meet customer demand, and as a result, negatively impacted revenue compared to expectations. The global supply chain constraints will limit our ability to captureOver the demand from our customers during fiscal 2022. We continue to maintain additional resources to help mitigate component constraint challenges and the operating inefficiencies COVID-19 has created, but note these inefficiencies place additional burden on operating results.

~~The~~past few quarters, global supply chain constraints have led to inflation in many of the components we acquire, as well as labor and operating costs. We expect the increase in costs to continue in the near future. Labor-related issues have become more pronounced likely as a result of COVID-19 and current economic conditions. We have been, and expect to continue to be, subject to such inflationary and general labor cost increases including in our Malaysia operations where the government has imposed a mandatory increase to the minimum wage that went into effect in our third quarter of fiscal 2022. While we have been largely able to mitigate the impacts of inflation through our contractual rights with customers on pricing, the pricing recoveries received may be dilutive to our operating margin. The inability to offset these costs in future periods or the impacts of continued inflation on end markets and our customers may affect our operating results, cash flows and inventory levels, which could increase as a result of higher component prices or the negative effects of inflation on customer end-market demand.

We believe ~~we are positioned with a strong~~our balance sheet is positioned to ~~face~~support the potential future challenges presented by ~~COVID-19.~~COVID-19 and other macro-economic pressures we are facing. As of the ~~first~~third quarter of fiscal 2022, cash and cash equivalents and restricted cash were ~~$218~~$278 million, while debt, finance lease obligations and other financing were ~~$338~~$435 million. To further ensure our ability to meet the needs of working capital investments to support anticipated revenue growth, we refinanced our revolving credit facility, expanding the maximum commitment from $350.0 million to $500.0 million. Borrowings under our Credit Facility as of ~~January 1,~~July 2, 2022 were ~~$140~~$240 million, leaving ~~$210~~$260 million of our revolving commitment of ~~$350~~$500.0 million available for use as of ~~January 1,~~July 2, 2022 as well as the ability to expand our revolving commitment to ~~$600~~$750 million upon mutual agreement with the bank. Refer to Note 3, "Debt, Finance Lease Obligations and Other Financing," in Notes to Condensed Consolidated Financial Statements and "Management’s Discussion and Analysis Liquidity and Capital Resources" in Part I, Item 2 for further information.

The recent conflict between Russia and Ukraine has negatively impacted the global economy and led to various economic sanctions being imposed by the U.S., United Kingdom, European Union and other countries against Russia. While the impacts of the conflict have not been material on our operating results, as we do not have operations or material customers or suppliers in either country, it is not possible to predict the broader consequences of this conflict.

See in particular the "Risk Factors" contained in our Annual Report on Form 10-K for the fiscal year ended October 2, 2021, "including "Our financial condition and results of operations may be materially adversely affected by the ongoing coronavirus (COVID-19) ~~outbreak" and~~ ~~"We~~outbreak", "We experience component shortages, price fluctuations and supplier quality concerns.", and "Plexus is a multinational corporation and operating in multiple countries exposes us to increased risks, including adverse local developments and currency risks."

2022

Table of Contents

RESULTS OF OPERATIONS

Consolidated Performance Summary. The following table presents selected consolidated financial data (dollars in millions, except per share data):


		Three Months Ended							Three Months Ended						Nine Months Ended
		January 1, 2022			January 2, 2021				July 2, 2022			July 3, 2021			July 2, 2022			July 3, 2021
Net sales	Net sales	$	817.5		$	830.4		Net sales	$	981.3		$	814.4		$	2,687.5		$	2,525.6
Cost of sales	Cost of sales	747.5			751.1			Cost of sales	887.7			740.3			2,447.4			2,281.3
Gross profit	Gross profit	70.0			79.3			Gross profit	93.6			74.1			240.1			244.3
Gross margin	Gross margin	8.6		%	9.5		%	Gross margin	9.5		%	9.1		%	8.9		%	9.7		%
Operating income	Operating income	30.5			46.9			Operating income	49.6			36.4			115.9			133.9
Operating margin	Operating margin	3.7		%	5.6		%	Operating margin	5.1		%	4.5		%	4.3		%	5.3		%
Other expense	Other expense	3.7			5.2			Other expense	6.3			3.5			14.5			12.9
Income tax expense	Income tax expense	3.4			5.4			Income tax expense	5.8			5.3			13.6			15.4
Net income	Net income	23.4			36.2			Net income	37.5			27.6			87.8			105.6
Diluted earnings per share	Diluted earnings per share	$	0.82		$	1.23		Diluted earnings per share	$	1.33		$	0.95		$	3.09		$	3.60
Return on invested capital*	Return on invested capital*	10.0		%	16.3		%	Return on invested capital*							11.5		%	15.9		%
Economic return*	Economic return*	0.7		%	8.2		%	Economic return*							2.2		%	7.8		%
*Non-GAAP metric; refer to "Return on Invested Capital ("ROIC") and economic return" below for more information and Exhibit 99.1 for a reconciliation.
*Non-GAAP metric; refer to "Return on Invested Capital ("ROIC") and economic return" below for more information and Exhibit 99.1 to this Quarterly Report on Form 10-Q for a reconciliation.								*Non-GAAP metric; refer to "Return on Invested Capital ("ROIC") and economic return" below for more information and Exhibit 99.1 to this Quarterly Report on Form 10-Q for a reconciliation.

Net sales. For the three months ended ~~January 1,~~July 2, 2022, net sales ~~decreased $12.9~~increased $166.9 million, or ~~1.6%~~20.5%, as compared to the three months ended ~~January~~July 3, 2021. For the nine months ended July 2, ~~2021. The decrease in~~2022, net sales was primarily driven by supply chain constraints, which has created limitations with meeting available customer demand and ramping new programs, partially offset by an increase in production ramps of new products with existing customers.increased $161.9 million, or 6.4%, as compared to the nine months ended July 3, 2021.

Net sales are analyzed by management by geographic segment, which reflects our reportable segments, and by market sector. Management measures operational performance and allocates resources on a geographic segment basis. Our global business development strategy is based on our targeted market sectors.

A discussion of net sales by reportable segment is presented below (in millions):


		Three Months Ended					Three Months Ended				Nine Months Ended
		January 1, 2022		January 2, 2021			July 2, 2022		July 3, 2021		July 2, 2022		July 3, 2021
Net sales:	Net sales:					Net sales:
AMER	AMER	$	277.3	$	327.6	AMER	$	342.6	$	318.9	$	931.1	$	1,011.2
APAC	APAC	491.7		451.3		APAC	586.3		446.9		1,611.9		1,357.1
EMEA	EMEA	72.9		78.7		EMEA	84.2		76.5		230.7		238.5
Elimination of inter-segment sales	Elimination of inter-segment sales	(24.4)		(27.2)		Elimination of inter-segment sales	(31.8)		(27.9)		(86.2)		(81.2)
Total net sales	Total net sales	$	817.5	$	830.4	Total net sales	$	981.3	$	814.4	$	2,687.5	$	2,525.6

AMER. Net sales for the three months ended ~~January 1,~~July 2, 2022 in the AMER segment ~~decreased $50.3~~increased $23.7 million, or ~~15.4%~~7.4%, as compared to the three months ended ~~January~~July 3, 2021. The increase in net sales was driven by a $26.8 million increase in production ramps of new products for existing customers, overall net increased customer end-market demand and increased pricing associated with inflated component prices, partially offset by the impact of supply chain constraints that have created limitations with meeting available customer demand. These increases were further offset by an $8.3 million decrease due to partial loss of business with customers and a $6.4 million decrease for end-of-life products.

During the nine months ended July 2, 2022, net sales in the AMER segment decreased $80.1 million, or 7.9%, as compared to the nine months ended July 3, 2021. The decrease in net sales was driven by a $55.5 million decrease for end-of-life products, a $39.0 million decrease due to partial loss of business with customers, $3.6 million due to a disengagement with a customer and

Table of Contents

supply chain constraints that have created limitations with meeting available customer demand. These decreases were partially offset by a $34.0 million increase in production ramps of new products for existing customers, overall net increased customer end-market demand and increased pricing associated with inflated component prices as well as a $5.0 million increase in production ramps for a new customer.

APAC. Net sales for the three months ended July 2, 2022 in the APAC segment increased $139.4 million, or 31.2%, as compared to the three months ended July 3, 2021. The increase in net sales was driven by overall net increased customer end-market demand and increased pricing associated with inflated component prices, a $25.0 million increase in production ramps of new products for existing customers and partial recovery from supply chain constraints that had previously created limitations with meeting available customer demand.

During the nine months ended July 2, 2022, net sales in the APAC segment increased $254.8 million, or 18.8%, as compared to the nine months ended July 3, 2021. The increase in net sales was driven by overall net increased customer end-market demand and increased pricing associated with inflated component prices as well as a $68.4 million increase in production ramps of new products for existing customers, partially offset by the impact of supply chain constraints that have created limitations with meeting available customer demand. These increases were further offset by a $31.9 million decrease for end-of-life products and a $5.4 million decrease for the loss of existing business.

EMEA. Net sales for the three months ended July 2, 2022 in the EMEA segment increased $7.7 million, or 10.1%, as compared to the three months ended July 3, 2021. The increase in net sales was driven by overall net increased customer end-market demand and increased pricing associated with inflated component prices.

During the nine months ended July 2, 2022, net sales in the EMEA segment decreased $7.8 million, or 3.3%, as compared to the nine months ended July 3, 2021. The decrease in net sales was driven by overall net decreased customer end-market demand, partially offset by a $6.7 million increase in production ramps of new products for existing customers.

Our net sales by market sector were as follows (in millions):


	Three Months Ended				Nine Months Ended
	July 2, 2022		July 3, 2021		July 2, 2022		July 3, 2021
Net sales:
Industrial	$	454.4	$	371.9	$	1,232.9	$	1,156.9
Healthcare/Life Sciences	400.8		324.5		1,098.5		993.5
Aerospace/Defense	126.1		118.0		356.1		375.2
Total net sales	$	981.3	$	814.4	$	2,687.5	$	2,525.6

Industrial. Net sales for the three months ended July 2, 2022 in the Industrial sector increased $82.5 million, or 22.2%, as compared to the three months ended July 3, 2021. The increase in net sales was driven by overall net increased customer end-market demand and increased pricing associated with inflated component prices as well as a $16.6 million increase in production ramps of new products for existing customers, partially offset by the impact of supply chain constraints that have created limitations with meeting available customer demand. The increase was further offset by a $9.1 million decrease due to partial loss of business with customers.

During the nine months ended July 2, 2022, net sales in the Industrial sector increased $76.0 million, or 6.6%, as compared to the nine months ended July 3, 2021. The increase in net sales was driven by overall net increased customer end-market demand and increased pricing associated with inflated component prices as well as a $26.5 million increase due to production ramps of new products for existing customers, partially offset by the impact of supply chain constraints that have created limitations with meeting available customer demand. The increase was further offset by a $39.3 million decrease due to partial loss of business with customers, $3.6 million due to a disengagement with a customer and an $18.2 million decrease for end-of-life products.

Healthcare/Life Sciences. Net sales for the three months ended July 2, 2022 in the Healthcare/Life Sciences sector increased $76.3 million, or 23.5%, as compared to the three months ended July 3, 2021. The increase in net sales was driven by overall net increased customer end-market demand and increased pricing associated with inflated component prices, a $31.8 million increase due to production ramps of new products for existing customers and a partial recovery of supply chain constraints that had previously created limitations with meeting available customer demand. These increases were partially offset by a $6.2 million decrease for end-of-life products.

Table of Contents

During the nine months ended July 2, 2022, net sales in the Healthcare/Life Sciences sector increased $105.0 million, or 10.6%, as compared to the nine months ended July 3, 2021. The increase in net sales was driven by overall net increased customer end-market demand and increased pricing associated with inflated component prices, a $59.8 million increase due to production ramps of new products for existing customers and a partial recovery of supply chain constraints that had previously created limitations with meeting available customer demand. These increases were partially offset by a $65.0 million decrease for end-of-life products and a $5.4 million decrease for the loss of existing business.

Aerospace/Defense. Net sales for the three months ended July 2, 2022 in the Aerospace/Defense sector increased $8.1 million, or 6.9%, as compared to the three months ended July 3, 2021. The increase was driven by a $7.0 million increase due to production ramps of new products for existing customers as well as overall net increased customer end-market demand.

During the nine months ended July 2, 2022, net sales in the Aerospace/Defense sector decreased $19.1 million, or 5.1%, as compared to the nine months ended July 3, 2021. The decrease was driven by net decreased customer end-market demand, inclusive of the impact of supply chain constraints that have created limitations with meeting available customer demand and ~~ramping new programs. The decrease in net sales was also driven by~~ a ~~$6.8~~$6.0 million decrease due to ~~a disengagement with a customer.~~end-of-life products. These decreases were partially offset by a ~~$12.4~~$22.4 million increase indue to production ramps of new products for existing customers.

~~Table of Contents~~

~~APAC.~~ ~~Net sales for the three months ended~~ ~~January 1, 2022~~ in the APAC segment increased $40.4 million, or 9.0%, as compared to the three months ended January 2, 2021. The increase in net sales was driven by overall net increased customer end-market demand, partially offset by the impact of supply chain constraints that have created limitations with meeting available customer demand and ramping new programs. The increase was also driven by a $20.2 million increase in production ramps of new products for existing customers. These increases were partially offset by a $7.2 million decrease for end-of-life products.

~~EMEA.~~ ~~Net sales for the three months ended~~ ~~January 1, 2022~~ ~~in the EMEA segment decreased $5.8 million, or 7.4%, as compared to the three months ended January 2, 2021.~~ ~~The decrease in net sales was driven by overall net decreased customer end-market demand.~~

~~Our net sales by market sector were as follows (in millions):~~

Three Months Ended
January 1, 2022 January 2, 2021
Net sales:
Industrial $ 363.8 $ 378.1
Healthcare/Life Sciences 344.5 319.3
Aerospace/Defense 109.2 133.0
Total net sales $ 817.5 $ 830.4

~~Industrial.~~ ~~Net sales for the three months ended~~ ~~January 1, 2022~~ in the Industrial sector decreased $14.3 million, or 3.8%, as compared to the three months ended January 2, 2021. The decrease was driven by supply chain constraints that have created limitations with meeting available customer demand and ramping new programs, partially offset by overall net increased customer end-market demand, and a $6.8 million decrease due to a disengagement with a customer. The decrease was partially offset by an increase of $14.0 million due to production ramps of new products with existing customers.

~~Healthcare/Life Sciences~~. ~~Net sales for the three months ended~~ ~~January 1, 2022~~ in the Healthcare/Life Sciences sector increased $25.2 million, or 7.9%, as compared to the three months ended January 2, 2021. The increase in net sales was driven by a $21.2 million increase in production ramps of new products with existing customers as well as overall net increased customer end-market demand, partially offset by the impact of supply chain constraints that have created limitations with meeting available customer demand and ramping new programs. The increase was partially offset by a $7.2 million decrease for end-of-life products, primarily as a result of decreased demand in critical care products likely due to COVID-19.

~~Aerospace/Defense~~. ~~Net sales for the three months ended~~ ~~January 1, 2022~~ in the Aerospace/Defense sector decreased $23.8 million, or 17.9%, as compared to the three months ended January 2, 2021. The decrease was driven by net decreased customer end-market demand, primarily with commercial aerospace customers likely due to COVID-19, as well as the impact of supply chain constraints that have created limitations with meeting available customer demand and ramping new programs.

Cost of sales. Cost of sales for the three months ended ~~January 1,~~July 2, 2022 ~~decreased $3.6~~ increased $147.4 million, or ~~0.5%~~19.9%, as compared to the three months ended ~~January~~July 3, 2021, while cost of sales for the nine months ended July 2, 2022 increased $166.1 million, or 7.3%, as compared to the nine months ended July 3, 2021. Cost of sales is comprised primarily of material and component costs, labor costs and overhead. For the three and nine months ended ~~January 1,~~July 2, 2022 and ~~January 2,~~the three and nine months ended July 3, 2021, approximately 89% to 90% of the total cost of sales was variable in nature and fluctuated with sales volumes. ~~Approximately~~Of these amounts, approximately 87% to 88% of ~~these~~the variable costs for the three and nine months ended July 2, 2022 and July 3, 2021, were related to material and component costs.

As compared to the three and nine months ended ~~January 2,~~July 3, 2021, the ~~decrease~~increase in cost of sales for the three and nine months ended ~~January 1,~~July 2, 2022 was primarily driven by the ~~decrease~~increase in net ~~sales. This was partially offset by~~sales, unfavorable customer mix, an increase in fixed costs, reduced labor productivity and ~~operational inefficiencies associated with supply chain constraints.~~increased labor costs.

Gross profit. Gross profit for the three months ended ~~January 1,~~July 2, 2022 ~~decreased $9.3~~increased $19.5 million, or ~~11.7%~~26.3%, as compared to the three months ended ~~January 2,~~July 3, 2021. Gross margin of ~~8.6%~~9.5% for the three months ended ~~January 1,~~July 2, 2022 ~~decreased 90~~increased 40 basis points compared to the three months ended ~~January~~July 3, 2021. The primary driver of the increase in gross profit and gross margin for the three months ended July 2, 2022 was the increase in net sales and reduced employee compensation and supplies costs associated with COVID-19, partially offset by unfavorable customer mix, increased fixed costs, reduced labor productivity and increased labor costs.

Gross profit for the nine months ended July 2, 2022 decreased $4.2 million, or 1.7%, as compared to the nine months ended July 3, 2021. Gross margin of 8.9% for the nine months ended July 2, 2022 decreased 80 basis points compared to the nine months ended July 3, 2021. The primary driver of the decrease in gross profit and gross margin ~~as compared to fiscal 2021~~for the nine months ended July 2, 2022 was ~~the decrease in net sales as well as the~~unfavorable customer mix, an increase in fixed costs, reduced labor productivity and ~~operational inefficiencies~~increased labor costs, partially offset by the increase in net sales and reduced employee compensation and supplies costs associated with ~~supply chain constraints.~~

~~Table of Contents~~

COVID-19.

Operating income. Operating income for the three months ended ~~January 1,~~July 2, 2022 ~~decreased $16.4~~increased $13.2 million, or ~~35.0%~~36.3%, as compared to the three months ended ~~January~~July 3, 2021. Operating margin of 5.1% for the three months ended July 2, ~~2021 as a~~2022 increased 60 basis points compared to the three months ended July 3, 2021. The primary driver of the increase in operating income and operating margin for the three months ended July 2, 2022 was the result of the ~~decrease~~increase in gross profit and gross margin along with a ~~$5.1~~$1.2 million decrease in restructuring and impairment charges, partially offset by a $6.4.million increase in selling and administrative expenses ("S&A"). The increase in S&A was primarily due to an increase in compensation costs.

Operating income for the nine months ended July 2, 2022 decreased $18.0 million, or 13.4%, as compared to the nine months ended July 3, 2021. Operating margin of 4.3% for the nine months ended July 2, 2022 decreased 100 basis points compared to the nine months ended July 3, 2021. The primary driver of the decrease in operating income and operating margin for the nine months ended July 2, 2022 was the result of the decrease in gross profit and gross margin along with a ~~$2.0~~$13.8 million increase in ~~restructuring and impairment charges.~~S&A. The increase in S&A was primarily due to an increase in bad debt expense compared to recovery of a previously reserved customer receivable received during the ~~three~~nine months ended ~~January 2,~~July 3, 2021, as well as increased compensation costs. ~~Operating margin~~

Table of ~~3.7% for the three months ended~~ Contents~~January 1, 2022~~ decreased 190 basis points compared to the three months ended January 2, 2021, primarily due to the decrease in gross margin as a result of the factors previously discussed, the increase in S&A expenses and increased restructuring and impairment charges associated with employee severance costs for a facility transition in the APAC region.

A discussion of operating income by reportable segment is presented below (in millions):


		Three Months Ended					Three Months Ended				Nine Months Ended
		January 1, 2022		January 2, 2021			July 2, 2022		July 3, 2021		July 2, 2022		July 3, 2021
Operating income (loss):	Operating income (loss):					Operating income (loss):
AMER	AMER	$	1.8	$	16.5	AMER	$	17.0	$	9.2	$	26.5	$	51.9
APAC	APAC	60.7		61.5		APAC	67.3		57.1		188.8		176.7
EMEA	EMEA	1.0		(1.0)		EMEA	2.6		0.1		4.0		(2.5)
Corporate and other costs	Corporate and other costs	(33.0)		(30.1)		Corporate and other costs	(37.3)		(30.0)		(103.4)		(92.2)
Total operating income	Total operating income	$	30.5	$	46.9	Total operating income	$	49.6	$	36.4	$	115.9	$	133.9

AMER. Operating income ~~decreased $14.7~~increased $7.8 million for the three months ended ~~January 1,~~July 2, 2022 as compared to the three months ended ~~January~~July 3, 2021, primarily as a result of an increase in net sales and a positive shift in customer mix, partially offset by increased fixed costs and increased labor costs.

During the nine months ended July 2, 2022, operating income in the AMER segment decreased $25.4 million as compared to the nine months ended July 3, 2021, primarily as a result of a decrease in net sales, increased fixed costs, reductions in labor productivity ~~attributable to supply chain constraints,~~and increased labor costs. There was also an increase in bad debt expense compared to recovery of a previously reserved customer receivable for the ~~three~~nine months ended ~~January 2, 2021, and increased fixed costs.~~July 3, 2021. This was partially offset by a positive shift in customer mix.

APAC. Operating income ~~decreased $0.8~~increased $10.2 million for the three months ended ~~January 1,~~July 2, 2022 as compared to the three months ended ~~January 2,~~July 3, 2021, primarily as a result of ~~reductions~~an increase in net sales and improvements in labor productivity, ~~attributable to supply chain constraints, an increase in fixed costs and~~partially offset by a negative shift in customer ~~mix. This was partially offset by~~mix and increased fixed costs.

During the nine months ended July 2, 2022, operating income in the APAC segment increased $12.1 million as compared to the nine months ended July 3, 2021, primarily as a result of an increase in net ~~sales.~~sales, partially offset by a negative shift in customer mix, increased fixed costs, reductions in labor productivity and increased labor costs.

EMEA. Operating income increased ~~$2.0~~$2.5 million for the three months ended ~~January 1,~~July 2, 2022 as compared to the three months ended ~~January~~July 3, 2021 primarily as a result of an increase in net sales, a positive shift in customer mix and improvements in labor productivity.

During the nine months ended July 2, 2022, operating income in the EMEA segment increased $6.5 million as compared to the nine months ended July 3, 2021, primarily as a result of a positive shift in customer ~~mix. This was~~mix and improvements in labor productivity, partially offset by a decrease in net sales.

Other expense. Other expense for the three months ended ~~January 1,~~July 2, 2022 ~~decreased $1.5~~ increased $2.8 million as compared to the three months ended ~~January 2,~~July 3, 2021. The ~~decrease~~increase in other expense was primarily due to an increase in foreign exchange losses of $1.2 million, an increase in factoring fees of $0.8 million and an increase in interest expense of $0.7 million.

Other expense for the nine months ended July 2, 2022 increased $1.6 million as compared to the nine months ended July 3, 2021. The increase in other expense was primarily due to an increase in foreign exchange losses of $1.0 million, an increase in factoring fees of $0.9 million, partially offset by a decrease in interest expense of ~~$1.0 million and a decrease of $0.5 million in foreign exchange losses.~~$0.8 million.

Income taxes. Income tax expense for the three and nine months ended ~~January 1,~~July 2, 2022 was ~~$3.4~~$5.8 million and $13.6 million, respectively, compared to ~~$5.4~~$5.3 million and $15.4 million for the three and nine months ended July 3, 2021, respectively. The increase for the three months ended ~~January~~July 2, ~~2021.~~2022 as compared to July 3, 2021 was primarily due to an increase in pre-tax book income and an increase in discrete tax expenses of $1.4 million, partially offset by the change in the geographic distribution of pre-tax book income. The decrease isfor the nine months ended July 2, 2022 as compared to July 3, 2021 was primarily due to a decrease in pre-tax book income ~~before taxes as well as additional discrete tax benefits~~and change in geographic distribution of ~~$0.6 million,~~pre-tax book income, partially offset by ~~a change~~an increase in ~~the geographic distribution~~discrete tax expenses of ~~worldwide earnings.~~$2.0 million.

Our annual effective tax rate varies from the U.S. statutory rate of 21.0% primarily due to the geographic distribution of worldwide earnings as well as a tax holiday granted to a subsidiary located in the APAC segment where we derive a significant portion of our earnings. Our effective tax rate may also be impacted by disputes with taxing authorities, tax planning activities, adjustments to uncertain tax positions and changes in valuation allowances.

The annual effective tax rate for fiscal 2022 is expected to be approximately 13.0% to 15.0% assuming no changes to tax laws.

Table of Contents

Net Income. Net income for the three months ended ~~January 1,~~July 2, 2022 ~~decreased $12.8~~ increased $9.9 million, or ~~35.4%~~35.9%, from the three months ended ~~January 2,~~July 3, 2021 to ~~$23.4~~$37.5 million. Net income increased primarily as a result of the increase in operating income, as previously discussed.

Net income for the nine months ended July 2, 2022 decreased $17.8 million, or 16.9%, from the nine months ended July 3, 2021 to $87.8 million. Net income decreased primarily as a result of the decrease in operating income, partially offset by the decrease in ~~other expense and~~ tax expense, as previously discussed.

Diluted earnings per share. Diluted earnings per share ~~decreased~~increased to ~~$0.82~~$1.33 for the three months ended ~~January 1,~~July 2, 2022 from ~~$1.23~~$0.95 for the three months ended ~~January~~July 3, 2021 primarily as a result of increased net income due to the factors previously discussed and a reduction in diluted shares outstanding due to repurchase activity under our share repurchase plans.

Diluted earnings per share decreased to $3.09 for the nine months ended July 2, 2022 from $3.60 for the nine months ended July 3, 2021 primarily as a result of decreased net income due to the factors previously discussed, ~~above,~~ partially offset by a reduction in diluted shares outstanding due to repurchase activity under our share repurchase plans.

~~Table of Contents~~

Return on Invested Capital ("ROIC") and economic return. We use a financial model that is aligned with our business strategy and includes a ROIC goal of 15%.

Non-GAAP financial measures, including ROIC and economic return, are used for internal management goals and decision making because such measures provide management and investors additional insight into financial performance. In particular, we provide ROIC and economic return because we believe they offer insight into the metrics that are driving management decisions because we view ROIC and economic return as important measures in evaluating the efficiency and effectiveness of our long-term capital requirements. We also use ROIC as a performance criteria in determining certain elements of compensation and certain compensation incentives are based on economic return performance.

We define ROIC as tax-effected operating income before restructuring and other special items divided by average invested capital over a rolling ~~two-quarter~~four-quarter period for the ~~first~~third quarter. Invested capital is defined as equity plus debt and operating lease liabilities, less cash and cash equivalents. Other companies may not define or calculate ROIC in the same way. ROIC and other non-GAAP financial measures should be considered in addition to, not as a substitute for, measures of our financial performance prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). We define economic return as ROIC less our weighted average cost of capital ("WACC").

We review our internal calculation of WACC annually. Our WACC is 9.3% for fiscal 2022 as compared to 8.1% for fiscal 2021. By exercising discipline to generate ROIC in excess of our WACC, our goal is to create value for our shareholders. For the ~~three~~nine months ended ~~January 1,~~July 2, 2022, ROIC of ~~10.0%~~11.5% reflects an economic return of ~~0.7%~~2.2%, based on our weighted average cost of capital of 9.3%. For the ~~three~~nine months ended ~~January 2,~~July 3, 2021, ROIC of ~~16.3%~~15.9% reflects an economic return of ~~8.2%~~7.8%, based on our weighted average cost of capital of 8.1% for that fiscal year.

For a reconciliation of ROIC, economic return and adjusted operating income (tax effected) to our financial statements that were prepared using GAAP, see Exhibit 99.1 to this quarterly report on Form 10-Q, which exhibit is incorporated herein by reference.

Refer to the table below, which includes the calculation of ROIC and economic return for the indicated fiscal ~~years~~period (dollars in millions):


		Three Months Ended							Nine Months Ended
		January 1, 2022			January 2, 2021				July 2, 2022			July 3, 2021
Adjusted operating income (tax effected)	Adjusted operating income (tax effected)	$	113.1		$	163.1		Adjusted operating income (tax effected)	$	135.2		$	159.1
Average invested capital	Average invested capital	1,135.3			1,002.1			Average invested capital	1,178.1			1,003.6
After-tax ROIC	After-tax ROIC	10.0		%	16.3		%	After-tax ROIC	11.5		%	15.9		%
WACC	WACC	9.3		%	8.1		%	WACC	9.3		%	8.1		%
Economic return	Economic return	0.7		%	8.2		%	Economic return	2.2		%	7.8		%

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents and restricted cash were ~~$218.4~~$277.8 million as of ~~January 1,~~July 2, 2022, as compared to $270.5 million as of October 2, 2021.

As of ~~January 1,~~July 2, 2022, ~~90.4%~~94% of our cash and cash equivalents balance was held outside of the U.S. by our foreign subsidiaries. Currently, we believe that our cash balance, together with cash available under our Credit Facility, will be sufficient to meet our liquidity needs and potential share repurchases, if any, for the next twelve months and for the foreseeable future.

~~Table of Contents~~

Our future cash flows from operating activities will be reduced by ~~$53.6~~$47.7 million due to cash payments for U.S. federal taxes on the deemed repatriation of undistributed foreign earnings that are payable over an eight year period that began in fiscal 2019 with the first payment. The table below provides the expected timing of these future cash outflows, in accordance with the following installment schedule for the remaining ~~five~~ years (in millions):


Remaining 2022		$	5.6
2023	2023	5.6		2023	$	5.5
2024	2024	10.6		2024	10.6
2025	2025	14.2		2025	14.2
2026	2026	17.6		2026	17.4
Total	Total	$	53.6	Total	$	47.7

Cash Flows. The following table provides a summary of cash flows (in millions):


		Three Months Ended					Nine Months Ended
		January 1, 2022		January 2, 2021			July 2, 2022		July 3, 2021
Cash(used in) provided by operating activities		$	(89.0)	$	6.7
Cash (used in) provided by operating activities						Cash (used in) provided by operating activities	$	(25.8)	$	131.5
Cash used in investing activities	Cash used in investing activities	(33.4)		(15.8)		Cash used in investing activities	(85.1)		(34.3)
Cash provided by (used in) financing activities	Cash provided by (used in) financing activities	70.0		(24.8)		Cash provided by (used in) financing activities	122.1		(179.1)

Operating Activities. Cash flows used byin operating activities were ~~$89.0~~$25.8 million for the ~~three~~nine months ended ~~January 1,~~July 2, 2022, as compared to cash flows provided by operating activities of ~~$6.7~~$131.5 million for the ~~three~~nine months ended ~~January 2,~~July 3, 2021. The decrease was primarily due to cash flow (reductions) improvements of:

•$~~(12.8)~~(17.8) million decrease in net income.

•$~~(218.1)~~(494.5) million in inventory cash flows ~~driven~~primarily attributable to efforts to mitigate supply chain constraints for certain components with longer lead times by ~~increased~~acquiring materials to support production of certain products in future quarters. This allows us to support our customers' continuity of supply for their customers. Supply chain constraints have also led to inflation in many of the components we acquire, increasing inventory. In addition, inventory levels have increased to support the ramp of customer programs. In addition, there are longer lead times for certain components as a result of supply chain constraints heightened by the COVID-19 outbreak increasing our inventory level as we maintain components for remainder of the product.

•$~~(73.7)~~(119.0) million in accounts receivable cash flows driven by increased net sales as well as timing of customer shipments ~~mix of customer payment terms~~ and ~~payments as well as decreased factoring activity.~~payments.

•$~~99.7~~166.2 million in accounts payables cash flows driven by increased purchasing activity to support the ramp of customer ~~programs.~~programs as well as supply chain constraints leading to inflation in many of the components we acquire.

•$~~65.8~~170.2 million in customer deposit cash flows driven by significant deposits received from ~~four~~ten customers in the current year to cover certain inventory balances associated with longer lead times as a result of supply chain ~~constraints heightened by the COVID-19 outbreak.~~constraints.

•$~~35.0~~131.7 million in other current and non-current liabilities cash flows driven by an increase in advance payments from customers.

•

~~$9.0 million in contract assets cash flows driven by decreased demand from customers who recognize revenue over time in the current year compared to consistent demand in the prior year.~~

Table of Contents

The following table provides a summary of cash cycle days for the periods indicated (in days):

Three Months Ended
January 1,
2022 January 2, 2021
Days in accounts receivable 66 53
Days in contract assets 12 12
Days in inventory 145 93
Days in accounts payable (87) (59)
Days in cash deposits (33) (19)
Annualized cash cycle 103 80

~~Table of Contents~~


	Three Months Ended
	July 2, 2022	July 3, 2021
Days in accounts receivable	57	52
Days in contract assets	12	13
Days in inventory	160	108
Days in accounts payable	(87)	(71)
Days in cash deposits	(40)	(22)
Annualized cash cycle	102	80

We calculate days in accounts receivable and contract assets as each balance sheet item for the respective quarter divided by annualized sales for the respective quarter by day. We calculate days in inventory, accounts payable and cash deposits as each balance sheet line item for the respective quarter divided by annualized cost of sales for the respective quarter by day. We calculate annualized cash cycle as the sum of days in accounts receivable, days in contract assets and days in inventory, less days in accounts payable and days in cash deposits.

As of ~~January 1,~~July 2, 2022, annualized cash cycle days increased ~~twenty-three~~22 days compared to ~~January 2,~~July 3, 2021 due to the following:

Days in accounts receivable for the three months ended ~~January 1,~~July 2, 2022 increased ~~thirteen~~five days compared to the three months ended ~~January 2,~~July 3, 2021. The increase is primarily attributable to the timing of customer shipments and payments and mix of customer payment terms, ~~and a decrease~~partially offset by an increase in factored receivables.

Days in contract assets for the three months ended ~~January 1,~~July 2, 2022 ~~remained flat~~decreased one day compared to the three months ended ~~January 2,~~July 3, 2021. The decrease is primarily attributable to increased net sales.

Days in inventory for the three months ended ~~January 1,~~July 2, 2022 increased ~~fifty-two~~52 days compared to the three months ended ~~January 2,~~July 3, 2021. The increase is primarily attributable to ~~increased~~efforts to mitigate supply chain constraints for certain components with longer lead times by acquiring materials to support production of certain products in future quarters. This allows us to support our customers' continuity of supply for their customers. Supply chain constraints have also led to inflation in many of the components we acquire, increasing inventory. In addition, inventory levels have increased to support the ramp of customer programs, as well as the decrease in net sales. In addition, there are longer lead times for certain components as a result of supply chain constraints heightened by the COVID-19 outbreak increasing our inventory level as we maintain components for remainder of the product.programs.

Days in accounts payable for the three months ended ~~January 1,~~July 2, 2022 increased ~~twenty-eight~~16 days compared to the three months ended ~~January 2,~~July 3, 2021. The increase is primarily attributable to increased purchasing activity ~~and~~to support the ramp of customer products as well as supply chain constraints leading to ~~obtain certain~~inflation in many of the components ~~heightened by the COVID-19 outbreak, as well as the decrease in net sales.~~we acquire.

Days in cash deposits for the three months ended ~~January 1,~~July 2, 2022 increased ~~fourteen~~18 days compared to the three months ended ~~January 2,~~July 3, 2021. The increase was primarily attributable to significant deposits received from ~~four~~nine customers to cover certain inventory balances.

Free Cash Flow. We define free cash flow ("FCF"), a non-GAAP financial measure, as cash flow (used in) provided by operations less capital expenditures. FCF was ~~$(122.2)~~$(110.8) million for the ~~three~~nine months ended ~~January 1,~~July 2, 2022 compared to ~~$(9.2)~~$97.1 million for the ~~three~~nine months ended ~~January 2,~~July 3, 2021, a decrease of ~~$113.0~~$207.9 million.

Non-GAAP financial measures, including FCF, are used for internal management assessments because such measures provide additional insight to investors into ongoing financial performance. In particular, we provide FCF because we believe it offers insight into the metrics that are driving management decisions. We view FCF as an important financial metric as it demonstrates our ability to generate cash and can allow us to pursue opportunities that enhance shareholder value. FCF is a non-GAAP financial measure that should be considered in addition to, not as a substitute for, measures of our financial performance prepared in accordance with GAAP.

Table of Contents

A reconciliation of FCF to our financial statements that were prepared using GAAP follows (in millions):


		Three Months Ended					Nine Months Ended
		January 1, 2022		January 2, 2021			July 2, 2022		July 3, 2021
Cash flows (used in) provided by operating activities	Cash flows (used in) provided by operating activities	$	(89.0)	$	6.7	Cash flows (used in) provided by operating activities	$	(25.8)	$	131.5
Payments for property, plant and equipment	Payments for property, plant and equipment	(33.2)		(15.9)		Payments for property, plant and equipment	(85.0)		(34.4)
Free cash flow	Free cash flow	$	(122.2)	$	(9.2)	Free cash flow	$	(110.8)	$	97.1

Investing Activities. Cash flows used in investing activities were ~~$33.4~~$85.1 million for the ~~three~~nine months ended ~~January 1,~~July 2, 2022 compared to ~~$15.8~~$34.3 million for the ~~three~~nine months ended ~~January 2,~~July 3, 2021. The increase in cash used in investing activities was due to a ~~$17.4~~$50.6 million increase in capital expenditures, primarily due to our manufacturing footprint expansion in Bangkok, Thailand.

We estimate funded capital expenditures for fiscal 2022 will be approximately ~~$100.0~~$110.0 million to ~~$120.0~~$120. 0 million, of which ~~$33.2~~$85.0 million was utilized through the first ~~three~~nine months of fiscal 2022. The remaining fiscal 2022 capital expenditures are anticipated to be used primarily for our manufacturing footprint expansion in Bangkok, Thailand, and to support new program ramps and replace older equipment.

~~Table of Contents~~

Financing Activities. Cash flows provided by financing activities were ~~$70.0~~$122.1 million for the ~~three~~nine months ended ~~January 1,~~July 2, 2022 compared to cash flows used in financing activities of ~~$24.8~~$179.1 million for the ~~three~~nine months ended ~~January 2,~~July 3, 2021. The increase was primarily attributable to an increase of ~~$83.6~~$273.0 million in net borrowings on the Credit Facility and a decrease of ~~$12.6~~$32.3 million in cash used to repurchase our common stock.

On August 20, 2019, the Board of Directors approved a share repurchase program under which we were authorized to repurchase $50.0 million of our common stock (the "2019 Program"). During the ~~three~~nine months ended ~~January 2,~~July 3, 2021, we completed the 2019 Program by repurchasing 73,560 shares under this program for $5.3 million at an average price of $72.44 per share.

On August 13, 2020, the Board of Directors approved a share repurchase program under which we were authorized to repurchase up to $50.0 million of our common stock (the "2021 Program"). On November 18, 2020, the Board of Directors approved an additional $50.0 million in share repurchase authority under the existing 2021 Program such that there then existed a total of $100.0 million in share repurchase authority under the program. The 2021 program commenced upon completion of the 2019 Program. During the three months ended ~~January 2,~~July 3, 2021, we repurchased ~~233,511~~291,898 shares under this program for ~~$17.5~~$27.3 million at an average price of ~~$74.70~~$93.53 per share. During the nine months ended July 3, 2021, the Company repurchased 874,706 shares under this program for $73.9 million at an average price of $84.45 per share.

On August 11, 2021, the Board of Directors approved a ~~new~~ share repurchase program under which we were authorized to repurchase up to $50.0 million of its common stock (the "2022 Program"). The 2022 Program commenced upon completion of the 2021 Program. The 2022 Program has no expiration. During the three months ended ~~January 1,~~July 2, 2022, we repurchased ~~110,440~~148,571 shares under this program for ~~$10.2~~$11.7 million at an average price of ~~$91.74~~$79.27 per share. During the nine months ended July 2, 2022, we repurchased 564,718 shares under this program for $46.9 million at an average price of $83.07 per share. As of ~~January 1,~~July 2, 2022, ~~$36.7 million of authority remained under~~we completed the 2022 ~~Program.~~Program, and there is no remaining authority for share repurchases.

All shares repurchased under the aforementioned programs were recorded as treasury stock.

On June 15, 2018, we entered into a Note Purchase Agreement (the “2018 NPA”) pursuant to which we issued an aggregate of $150.0 million in principal amount of unsecured senior notes, consisting of $100.0 million in principal amount 4.05% Series A Senior Notes, due on June 15, 2025, and $50.0 million in principal amount of 4.22% Series B Senior Notes, due on June 15, 2028 (collectively, the “2018 Notes”), in a private placement. The 2018 NPA includes customary operational and financial covenants with which we are required to comply, including, among others, maintenance of certain financial ratios such as a total leverage ratio and a minimum interest coverage ratio. The 2018 Notes may be prepaid in whole or in part at any time, subject to payment of a make-whole amount; interest on the 2018 Notes is payable semiannually. As of ~~January 1,~~July 2, 2022, we were in compliance with the covenants under the 2018 NPA.

On ~~May 15, 2019,~~June 9, 2022, we refinanced our then-existing senior unsecured revolving credit facility (as amended by that certain Amendment No. 1 to Credit Agreement dated April 29, 2020, the "Prior Credit Facility") by entering into a new five-year ~~senior unsecured~~ revolving credit facility ~~(referred~~(collectively with the Prior Credit Facility, referred to as the "Credit Facility"), which expanded the maximum commitment from ~~$300.0~~$350.0 million to ~~$350.0~~$500.0 million and extended the maturity from ~~July 5, 2021 to~~ May 15, ~~2024.~~2024 to June 9, 2027. The maximum commitment under the Credit Facility may be further increased to ~~$600.0~~$750.0 million, generally by mutual agreement of the lenders and us, subject to certain customary conditions. During ~~fiscal~~the nine months ended July 2, 2022, the

Table of Contents

highest daily borrowing was ~~$186.0~~$327.0 million; the average daily borrowings were ~~$117.9~~$204.9 million. We borrowed ~~$181.0~~$524.0 million and repaid ~~$96.0~~$339.0 million of revolving borrowings ~~("revolving commitment")~~ under the Credit Facility during ~~fiscal~~the nine months ended July 2, 2022. As of ~~January 1,~~July 2, 2022, we were in compliance with all financial covenants relating to the Credit Facility, which are generally consistent with those in the 2018 NPA discussed above. We are required to pay a commitment fee on the daily ~~unused revolving commitment~~Credit Facility based on our leverage ratio; the fee was ~~0.125%~~0.15% as of ~~January 1,~~July 2, 2022.

To further ensure our ability to meet our working capital and fixed capital requirements, on April 29, 2020, we entered into Amendment No. 1 to the Credit Facility (the "Amendment") in response to the COVID-19 outbreak, which amended the Credit Facility, dated as of May 15, 2019. The Amendment modified certain provisions of the Credit Facility to, among other things, provide Term Loans for $138.0 million. Term Loans borrowed under the new facility were funded in a single draw on May 4, 2020 and were scheduled to mature on April 28, 2021. On January 29, 2021, we terminated the Term Loans through repayment of the $138.0 million outstanding using borrowings from the revolving commitment under the Credit Facility. Outstanding Term Loans bore interest, at our option, at a eurocurrency rate (subject to a floor of 1.0%) plus a margin of 1.75% per annum or at a base rate (subject to a floor of 2.0%) plus a margin of 0.75% per annum.

The Credit Facility and the 2018 NPA allow for the future payment of cash dividends or the repurchase of shares provided that no event of default (including any failure to comply with a financial covenant) exists at the time of, or would be caused by, the dividend payment or the share repurchases. We have not paid cash dividends in the past. However, we evaluate from time to time potential uses of excess cash, which in the future may include share repurchases above those already authorized, a special dividend or recurring dividends.

~~Table of Contents~~

We have Master Accounts Receivable Purchase Agreements with MUFG Bank, New York Branch (formerly known as The Bank of Tokyo-Mitsubishi UFJ, Ltd.) (the "MUFG RPA"), HSBC Bank (China) Company Limited, Xiamen branch (the "HSBC RPA") and other unaffiliated financial institutions, under which we may elect to sell receivables, at a discount, on an ongoing basis. These facilities are uncommitted facilities. The maximum facility amount under the MUFG RPA as of ~~January 1,~~July 2, 2022 is $340.0 million. The maximum facility amount under the HSBC RPA as of ~~January 1,~~July 2, 2022 is $60.0 million. The MUFG RPA will be automatically extended each year unless any party gives no less than 10 days prior notice that the agreement should not be extended. The terms of the HSBC RPA are generally consistent with the terms of the MUFG RPA previously discussed.

We sold ~~$148.0~~$213.6 million and ~~$198.4~~$180.6 million of trade accounts receivable under these programs during the three months ended ~~January 1,~~July 2, 2022 and ~~January 2,~~July 3, 2021, respectively, in exchange for cash proceeds of ~~$147.5~~$212.3 million and ~~$197.8~~$180.1 million, respectively.

We sold $563.8 million and $574.6 million of trade accounts receivable under these programs during the nine months ended July 2, 2022 and July 3, 2021, respectively, in exchange for cash proceeds of $561.3 million and $573.0 million, respectively.

As of ~~January 1,~~July 2, 2022 and October 2, 2021, ~~$151.0~~$216.9 million and $176.0 million, respectively, of accounts receivables sold under trade accounts receivable programs and subject to servicing by us remained outstanding and had not yet been collected.

In all cases, the sale discount was recorded within "Miscellaneous, net" in the Condensed Consolidated Statements of Comprehensive Income in the period of the sale. For further information regarding the receivable sale programs, see Note 13, "Trade Accounts Receivable Sale Programs," in Notes to Condensed Consolidated Financial Statements.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents, potential borrowings under the Credit Facility and our leasing capabilities should be sufficient to meet our working capital and fixed capital requirements, as well as execution upon our share repurchase authorizations as management deems appropriate, for the next twelve months. We believe our balance sheet is positioned to support the potential future challenges presented by COVID-19 and other macro-economic factors, including increased working capital requirements associated with longer lead time for components, increased component and labor costs, and operating inefficiencies due to supply chain constraints or workplace safety restrictions. As of the end of the ~~first~~third quarter of fiscal 2022, cash and cash equivalents and restricted cash were ~~$218~~$278 million, while debt, finance lease obligations and other financing were ~~$338~~$435 million. ~~We have significant funding availability through~~To further ensure our ~~Credit Facility, should future~~ability to meet the needs ~~arise.~~of working capital investments to support anticipated revenue growth, we refinanced our credit facility, expanding the maximum commitment from $350.0 million to $500.0 million, as discussed above. If our future financing needs increase, then we may need to arrange additional debt or equity financing. Accordingly, we evaluate and consider from time to time various financing alternatives to supplement our financial resources. However, we cannot be assured that we will be able to make any such arrangements on acceptable ~~terms.~~terms or at all.

2831

Table of Contents

DISCLOSURE ABOUT CRITICAL ACCOUNTING ~~POLICIES~~ESTIMATES

Our critical accounting ~~policies~~estimates are disclosed in our 2021 Annual Report on Form 10-K. During the ~~first~~third quarter of fiscal 2022, there were no material changes.

NEW ACCOUNTING PRONOUNCEMENTS

See Note 1, "Basis of Presentation," in Notes to Condensed Consolidated Financial Statements regarding recent accounting pronouncements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk from changes in foreign exchange and interest rates. We selectively use financial instruments to reduce such risks. We do not use derivative financial instruments for speculative purposes.

Foreign Currency Risk

Our international operations create potential foreign exchange risk. Our policy is to selectively hedge our foreign currency denominated transactions in a manner that partially offsets the effects of changes in foreign currency exchange rates. We typically use foreign currency contracts to hedge only those currency exposures associated with certain assets and liabilities denominated in non-functional currencies. Corresponding gains and losses on the underlying transaction generally offset the gains and losses on these foreign currency hedges. We cannot predict changes in currency rates, nor the degree to which we will be able to manage the impacts of currency exchange rate ~~changes, including the impacts on currency exchange rates related to the COVID-19 outbreak.~~changes. Such changes could have a material effect on our business, results of operations and financial condition.

Our percentages of transactions denominated in currencies other than the U.S. dollar for the indicated periods were as follows:


		Three Months Ended			Three Months Ended
		January 1, 2022	January 2, 2021		July 2, 2022	July 3, 2021
Net Sales	Net Sales	10%	10%	Net Sales	9%	10%
Total Costs	Total Costs	18%	16%	Total Costs	15%	16%

We have evaluated the potential foreign currency exchange rate risk on transactions denominated in currencies other than the U.S. dollar for the periods presented above. Based on our overall currency exposure, as of ~~January 1,~~July 2, 2022, a 10.0% change in the value of the U.S. dollar relative to our other transactional currencies would not have a material effect on our financial position, results of operations, or cash flows.

Interest Rate Risk

We have financial instruments, including cash equivalents and debt, which are sensitive to changes in interest rates. The primary objective of our investment activities is to preserve principal, while maximizing yields without significantly increasing market risk. To achieve this, we limit the amount of principal exposure to any one issuer. We cannot predict changes in interest ~~rates, including the impacts on interest rates related to the COVID-19 outbreak.~~rates.

As of ~~January 1,~~July 2, 2022, our only material interest rate risk iswas associated with our Credit Facility. ~~Revolving commitments~~Borrowings under the Credit Facility bear interest, at ~~our~~the Company's option, at ~~a eurocurrency or base rate~~(a)(1) for borrowings denominated in U.S. dollars, the Term Secured Overnight Financing Rate ("SOFR"), (2) for borrowings denominated in pounds sterling, the Daily Simple Risk-Free Rate, plus, in each case of (a)(1) and (2), 10 basis points, (b) for borrowings denominated in euros, the EURIBOR Rate plus a statutory reserve rate, or (c) an Alternate Base Rate equal to the highest of (i) 100 basis points per annum, (ii) the prime rate last quoted by The Wall Street Journal (or, if not quoted, as otherwise provided in the Credit Facility), (iii) the greater of the federal funds effective rate and the overnight bank funding rate in effect on such day plus, in each case, 50 basis points per annum (or, if neither are available, as otherwise provided in the Credit Facility), and (iv) Term SOFR for a one month interest period on such day plus 110 basis points, plus, in each case of (a), (b), and (c), an applicable interest rate margin based on ~~our then-current leverage ratio (as defined~~the Company's then current consolidated total indebtedness (minus certain unrestricted cash and cash equivalents in ~~the Credit Facility).~~an amount not to exceed $100 million) to consolidated EBITDA. As of ~~January 1,~~July 2, 2022, the borrowing rate under the Credit Facility was ~~LIBOR~~SOFR plus 1.10%. Borrowings under the 2018 NPA are based on a fixed interest rate, thus mitigating much of our interest rate risk. Based on our overall interest rate exposure, as of ~~January 1,~~July 2, 2022, a 10.0% change in interest rates would not have a material effect on our financial position, results of operations, or cash flows.

2932

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures designed to ensure that the information the Company must disclose in its filings with the Securities and Exchange Commission ("SEC") is recorded, processed, summarized and reported on a timely basis. The Company’s Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") have reviewed and evaluated, with the participation of the Company’s management, the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") as of the end of the period covered by this report (the "Evaluation Date"). Based on such evaluation, the CEO and CFO have concluded that, as of the Evaluation Date, the Company’s disclosure controls and procedures are effective, at the reasonable assurance level, (a) in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act, and (b) in assuring that information is accumulated and communicated to the Company’s management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

During the ~~first~~third quarter of fiscal 2022 there have been no changes in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1A. Risk Factors

In addition to the risks and uncertainties discussed herein, particularly those discussed in the “Safe Harbor” Cautionary Statement and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in Part I, Item 2, see the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended October 2, 2021 that have had no material changes.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides the specified information about the repurchases of shares by us during the three months ended ~~January 1,~~July 2, 2022:

Period Total number of shares purchased Average price paid per share Total number of shares purchased as part of publicly announced plans or programs Maximum approximate dollar value of shares that may yet be purchased under the plans or programs (1)
October 3, 2021 -
October 30, 2021 31,216 $ 93.41 31,216 $ 43,960,950
October 31, 2021 -
November 27, 2021 37,160 91.40 37,160 40,564,577
November 28, 2021 -
January 1, 2022 42,064 90.79 42,064 $ 36,745,401
110,440 $ 91.74 110,440


Period	Total number of shares purchased	Average price paid per share		Total number of shares purchased as part of publicly announced plans or programs	Maximum approximate dollar value of shares that may yet be purchased under the plans or programs (1)
April 3, 2022 - April 30, 2022	137,120	$	79.03	137,120	$	905,814
May 1, 2022- May 28, 2022	11,451	82.17		11,451	—
May 29, 2022 - July 2, 2022	—	—		—	$	—
	148,571	$	79.27	148,571

(1) On August 11, 2021, the Board of Directors approved a ~~new~~ share repurchase program that authorizes the Company to repurchase up to $50.0 million of its common stock (the "2022 Program"). The 2022 Program commenced upon completion of the 2021 Program during the fourth quarter of fiscal 2021. The ~~2022 Program has no expiration. The~~ table above reflects ~~the maximum dollar amount~~that there was nothing remaining available for purchase under the 2022 Program as of ~~January 1, 2022.~~

July 2, 2022, as the Company had completed the 2022 Program.

3033

Table of Contents

ITEM 6. EXHIBITS

The list of exhibits is included below:



Exhibit No.						Exhibit
10.1						~~Suspension of Rights under~~Amended and Restated Credit Agreement, ~~relating~~dated June 9, 2022, by and among Plexus Corp., certain of its subsidiaries from time to ~~LIBOR.~~
~~10.2~~						~~Summary of Directors' Compensation~~ ~~effective~~ ~~January 1,~~time party thereto as borrowers, the lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 13, 2022 by Plexus Corp.).*
31.1						Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
31.2						Certification of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
32.1						Certification of the CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2						Certification of the CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
99.1						Reconciliation of ROIC to GAAP and Economic Return Financial Statements.
101						The following materials from Plexus Corp.’s Quarterly Report on Form 10-Q for the fiscal quarter ended ~~January 1,~~July 2, 2022, formatted in Inline Extensible Business Reporting Language ("XBRL"): (i) the Condensed Consolidated Statements of Comprehensive Income, (ii) the Condensed Consolidated Balance Sheets, (iii) the Condensed Consolidated Statements of Shareholders’ Equity, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.
101.INS						Inline XBRL Instance Document (the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document).
101.SCH						Inline XBRL Taxonomy Extension Schema Document.
101.CAL						Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB						Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE						Inline XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF						Inline XBRL Taxonomy Extension Definition Linkbase Document.
104						The cover page from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended ~~January 1,~~July 2, 2022, formatted in Inline XBRL and contained in Exhibit 101.

3134

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Plexus Corp.

Registrant

Date:

~~February 4,~~August 5, 2022

/s/ Todd P. Kelsey

Todd P. Kelsey

Chief Executive Officer

Date:

~~February 4,~~August 5, 2022

/s/ Patrick J. Jermain

Patrick J. Jermain

Executive Vice President and Chief Financial Officer

3235